

CURRICULUM VITAE

Stephen P. Salloway, MD, MS

PERSONAL INFO

Current Position Professor of Neurology and Psychiatry
Brown Medical School

Director of Neurology
Butler Hospital
345 Blackstone Boulevard
Providence, RI 02906

Staff Neurologist
Department of Neurology
Rhode Island Hospital
593 Eddy Street
Providence, RI 02903

Business Telephone 401-455-6403
401-444-8795
401-455-6405 (fax)

Email Stephen_Salloway@Brown.edu

EDUCATION

1971-1975 Antioch College, B.A. - Psychology
1979-1981 University of California, Berkeley, M.S. - Medical Psychology
1981-1985 Stanford Medical School, M.D.

POSTGRADUATE TRAINING

1985-1986 Hospital of St. Raphael, New Haven, CT - Rotating Medical Internship
1986-1988 Yale University Department of Psychiatry - Psychiatry Resident
1988-1991 Yale University Department of Neurology - Neurology Resident
1990-1991 Yale University - Neurology Chief Resident

POSTGRADUATE HONORS AND AWARDS

1975-1977 Thomas J. Watson Fellow
1981-1985 Roland Jackson Scholar - fellowship support for medical training and research
1984 Rock Sleyster Award -- National AMA Scholarship in Psychiatry
1985 Stanford University Primary Care Program Award for Outstanding Achievement
in Clinical Teaching
1985 Stanford Medical School - Honors in Research
1987-1989 American Psychiatric Association Burroughs-Wellcome Fellow

Curriculum Vitae:

Stephen P. Salloway, MD, MS

- | | |
|--------|--|
| 1995 | Fellow, Summer Geriatric Research Institute American Association of Geriatric Psychiatry, UC San Diego |
| 1995-6 | Surdna Foundation Fellow for Geriatric Research - Brown University |
| 1995 | Outstanding Teaching Award - Brown University Department of Psychiatry and Human Behavior |
| 1996 | Distinguished Visiting Professor Wilford Hall Medical Center, San Antonio, Texas |
| 1998 | Care New England Care Awards Honorable Mention, Butler Hospital Memory Disorders Program |
| 1999 | Brown University Honorary Master of Arts Eundem |
| 2000 | Fellow, American Neuropsychiatric Association |
| 2001 | Outstanding Teaching Award for Undergraduate Medical Student Education, Brown Medical School |
| 2004 | Fellow, American Academy of Neurology |
| 2004 | Dean's Teaching Excellence Award, Brown Medical School |
| 2006 | Dean's Teaching Excellence Award, Brown Medical School |

MILITARY SERVICE None

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Certification: National Board of Medical Examiners
American Board of Neurology, 1991
American Board of Psychiatry, Eligible

Licenses: Connecticut, July 1987-August 1991
Rhode Island, July 1991-present

ACADEMIC APPOINTMENTS

- | | |
|--------------|---|
| 1983-1985 | Lecturer in Primary Care Internal Medicine, Stanford Medical School |
| 1990-1991 | Instructor in Neurology, Yale University School of Medicine |
| 1991-1998 | Assistant Professor, Department of Clinical Neurosciences, Brown Medical School |
| 1993-1998 | Assistant Professor, Department of Psychiatry and Human Behavior Brown Medical School |
| 1998-2004 | Associate Professor; Department of Clinical Neurosciences, Brown Medical School |
| 1998-2004 | Associate Professor; Department Psychiatry and Human Behavior, Brown Medical School |
| 2004-present | Professor, Department of Clinical Neurosciences, Brown Medical School |
| 2004-present | Professor, Department Psychiatry and Human Behavior, Brown Medical School |

HOSPITAL APPOINTMENTS

1987-1991 Emergency Psychiatric Privileges, Hospital of St. Raphael, New Haven, CT

Curriculum Vitae:

Stephen P. Salloway, MD, MS

1990-1991 Staff Physician, West Haven VA Medical Center
1991-present Director of Neurology, Butler Hospital, Providence, RI
1991-present Neurology Staff, Rhode Island Hospital, Providence, RI
1992-present Co-director, Laboratory for Quantitative Neuroimaging, Butler Hospital
1997-present Director, Butler Hospital Memory and Aging Program

OTHER APPOINTMENTS

EDITORIAL BOARD

1994-present Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences
1997-2000 Editorial Advisory Board, GeroPsychiatry Report
2004-2007 Editorial Board Applied Neurology

GUEST EDITOR

Salloway S, Duffy J, Malloy P, eds. The Frontal Lobes and Neuropsychiatric Illness. Fall issue of the Journal of Neuropsychiatry and Clinical Neurosci 1994;6:341-477.

Salloway S, Malloy P, Cummings J. The neuropsychiatry of limbic and subcortical disorders. Summer 1997 issue of the Journal of Neuropsychiatry and Clinical Neurosciences 1997;9:403-600.

REVIEWER

Journals

Aging and Mental Health, 2006-present
Alzheimer's Disease and Associated Disorders, 2004-present
Alzheimer's and Dementia, 2007-present
American Journal of Geriatric Psychiatry, 2000-present
American Journal of Psychiatry, 2001-present
American Journal of Psychiatry and the Law, 2000-present
Annals of Internal Medicine, 2001-present
Archives of Neurology, 2005-present
BMC Geriatrics, 2007-present
Canadian Journal of Neurological Sciences, 2006-present
CNS Spectrums, 2000-present
Dementia and Geriatric Cognitive Disorders, 2005-present
European Journal of Neurology 2005-present
Expert Opinion-2007-present
International Journal of Psychiatry in Clinical Practice, 2006-present
International Psychogeriatrics, 2006-present
Journal of Affective Disorders, 1997-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Journal of Clinical Psychiatry, 1997-present

Journal of the American Geriatrics Society, 2007-present

Journal of Geriatric Psychiatry and Neurology, 1998-present

Journal of Neurology, 2006-present

Journal of Neuropsychiatry and Clinical Neurosciences, 1993-present

Medical Letter, 2006-present

Neurobiology of Aging, 1998-present

Neuroepidemiology, 2001-present

Neurology, 2002-present

Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1993-present

Neuropsychopharmacology, 2001-present

New England Journal of Medicine, 2008-present

Psychopharmacology 2003-present

Psychosomatics, 1999-present

Southern Medical Journal, 1998-present

Stroke, 2001-present

Tohoku Journal of Experimental Medicine, 2006-present

National Institutes of Health

National Institute on Aging Neuroscience Branch Ad-hoc grant reviewer, 2001-present

NIMH Advisory Panel "Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline," 2003-present

NINDS Genetics of Vascular Cognitive Impairment Study Group, 2004-present

NINDS Special Emphasis Panel ZNS1 SNRB-S, 2004

Adult Psychopathology and Disorders of Aging IRG, February, 2005-present

NINDS Vascular Cognitive Impairment Harmonization Criteria Workshop, April, 2005

Professional Societies, Universities and Research Foundations

Alzheimer's Association and Related Disorders Inc., 1994-present

Alzheimer's Foundation of America Medical Advisory Board, 2003-present

American Academy of Neurology, 1994-present

American Neuropsychiatric Association, 1991-present

American Psychiatric Association, 1993-present

Harvard University Center for Neurodegeneration and Repair External Peer Review Committee, 1999-2004

Institute for the Study of Aging Scientific Review Board, 2003-present

The Michael J Fox Foundation for Parkinson's Disease Research, 2008-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

The New York Academy of Sciences, 1997-present

The Wellcome Trust, 1997-present

Book Publishers

American Psychiatric Press Inc., 1995-present

Cambridge University Press, 1995-present

F.A. Davis Publishers, 1991-present

John Wiley and Sons, 1994-present

Mosby Publishers, 1995-present

Oxford University Press, 1997-present

Swets and Zeitlinger, 1997-present

Internet Sites

WebMD, 2001-present

COLUMNIST

Psychiatric Times- The Aging Brain Column, 1997-present

CONSULTANT FOR DRUG DEVELOPMENT

Hoechst, Marion, Roussel Dementia Advisory Panel, 1997-2002

Eisai, Alzheimer's Disease Program, 1998-present

Bayer, Dementia Advisory Panel, 1998-2003

Novartis Neuroscience, 1999-present

Pfizer Alzheimer's Disease Development Program 1999-present

Consultant, Dementia Research, Janssen Pharmaceutica 2000-present

Sention Inc., Dementia Drug Development, 2002-2005

Sanofi-Aventis Alzheimer's Disease, 2005-present

Elan Alzheimer's Disease, 2007-present

HOSPITAL COMMITTEES

Member, Emergency Medical Committee, Butler Hospital, 1991-1996

Member, Executive Committee, Medical Staff Association, Butler Hospital, 1994-2000

UNIVERSITY COMMITTEES

Member, Stanford Medical School Medical Ethics Committee, 1983-1985

Member, Yale Hillel Medical Ethics Study Section, 1986-1991

Member, Brown University Brain Imaging Center Planning Committee, 1994-1996

Associate Director, Brown University Geriatric Neuropsychiatry Research and Treatment Program, 1994-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Member, Brown University Biomedical Computing Committee, 1995-1998
Member, Brown University Geriatric Psychiatry Fellowship Planning Committee, 1997-present
Member, Brown University Psychiatric Residency Curriculum Committee, 1997-present
Member, Brown University Department of Psychiatry Education Committee, 1997-present
Member, Providence VA/Brown University Geriatric Psychiatry Faculty Search Committee, 1997-2000
Member, Brown University Neurology Residency Education Committee, 1998-present
Member, Brown University Greer Professorship/Director of the Division of Geriatric Medicine Search Committee, 1998 -1999
Member, Brown University Psychiatry Residency Research Track Planning Committee, 1998-present
Member, Brown University Surdna Fellowship Review Committee, 1998-present
Reviewer, Royce Fellowship Committee, 2000-present
Member, Brown MRI Research Facility Executive Committee, 2000-present
Co-Director, Brown Department of Psychiatry Imaging Core, 2000-present
Member, Brown Medical School Director of Pediatric Neurology Search Committee, 2001-2002
Member-Departments of Psychiatry and Psychology Research Planning Committee, 2002-present
Member-Steering Committee, Brown Cooperative for Translational Brain Research, 2002-present
Member, Department of Clinical Neurosciences Promotions Committee, 2004-present

NATIONAL COMMITTEES:

Member, Consultation-Liaison Committee, American Psychiatric Association, 1987-1989
Chairman, Scientific Program Committee, American Neuropsychiatric Association, 1993-1995
President, American Neuropsychiatric Association, 1997-1998
Member, Old-Old Depression Research Consortium, 1998-present
Member, International Neuropsychological Society Scientific Program Committee, 2003-4
Member, Data Safety Monitoring Board, Rasgaline for Treatment of Mild-Moderate Alzheimer's Disease, Eisai Inc., 2004-2005.
Member, Institute for the Study of Aging Working Group on Guidelines for the Treatment of Alzheimer's Disease in the Managed Care Setting in New York City on October 10, 2005
Member, Medical Advisory Board. Alzheimer's Federation of America, 2004-present
Member, Guidelines for the Treatment of Dementia Panel, American Academy of Neurology, 2006-present
Member, Scientific Advisory Board. CADASIL: Together We Have Hope Foundation, 2006-present
Co-chair, Safety Evaluation Committee, Merck amyloid vaccine trial V950-001, 2007-present

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Member, Steering Committee ELND005-AD201–A *Phase II, Double Blind, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of Oral ELND005 in Mild to Moderate Alzheimer's Disease*. 2008-present.

INTERNATIONAL COMMITTEES:

Member, Advisory Panel, Third International Neuropsychiatry Congress Scientific Program Committee, Kyoto, Japan, 2000, 1997-2000

Member, Eisai/Pfizer International Advisory Board on Vascular Dementia, 2001-present

Member, Executive Committee International Neuropsychiatry Congress Planning Committee, 1998-present

Co Chair: International working group to revise the NINDS vascular dementia criteria for the International Society for Vascular Behavioral and Cognitive Disorders, 2002-present

Member, International Stroke Society to Develop an Organizing World Federation Committee for Stroke and Vascular Dementia, 2002-present

Member, Vascular Risk Factors and Dementia: Raising Risk Awareness Study Group, Madrid, Spain, October, 2005.

Member, International CADASIL Study Steering Committee, Eisai, 2005-present

Member, Scientific Program Committee, 3rd Congress of the International Society for Vascular Behavioral and Cognitive Disorders, 2006-present

Member, Dimebon phase 3 Data Monitoring Committee, 2008-present

MEMBERSHIP IN SOCIETIES

2004-present American Neurological Association

2008-present International Society to Advance Alzheimer Research and Treatment

1988-present American Neuropsychiatric Association
1995-7 Associate Director, 1997-8 President, 1993-5 Chair Scientific Program Committee, Member, Committee on Research

1989-present American Academy of Neurology,
Neuroimaging Section, Geriatric Neurology Section
Behavioral Neurology Section

1994-present Society for Neuroscience

1994-present Behavioral Neurology Society

2003-present International College of Geriatric Psychoneuropharmacology

2002-present International Society for Vascular Behavioral and Cognitive Disorders

2000-present American Association of Geriatric Psychiatry Affiliate Member

2004-present International Psychogeriatrics Association

1987-1997 American Psychiatric Association
Consultation - Liaison Committee, 1987-1989

Curriculum Vitae:

Stephen P. Salloway, MD, MS

1986-1995 American Medical Association

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Salloway S, Price L, Charney D, Shapiro M. Multiple sclerosis Presenting as major depression: A diagnosis suggested by MRI but not CT Scan. *J Clin Psychiatry* 1988; 364-366.
2. Salloway S, Southwick S, Sadowsky M. Opiate withdrawal Presenting as post-traumatic stress disorder. *Hospital and Community Psychiatry* 1990;41:666-7.
3. Fogel B, Salloway S, McNamara E, Duffy J. Skeptics and enthusiasts in neuropsychiatry *J Neuropsychiatry and Clin Neurosci* 1992;4:458-462.
4. Karper L, Salloway S, Seibyl J, Krystal J. Prolonged post-ictal encephalopathy in two patients following clozapine-induced seizures. *J Neuropsychiatry and Clin Neurosci* 1992;4:454-457.
5. Daly J, Salloway S. Clozapine-induced seizures and EEG changes. *Jefferson Journal of Psychiatry* 1993; 11:36-42.
6. Salloway S, Tate C, Rogg J. Clinicopathological case conference: Behavior change, hallucinations and memory loss in a twenty-five year old man. *J Neuropsychiatry and Clin Neurosci* 1993; 5:435-441.
7. Salloway S, Cummings J, Subcortical disease and neuropsychiatric illness. *J Neuropsychiatry and Clin Neurosci* 1994;6:93-99.
8. Daly J, Salloway S. Dopamine receptors in the human brain. *Psychiatric Times* 1994;11:27-32.
9. Campbell J, Duffy J, Salloway S. Treatment strategies for dysexecutive syndromes. *J Neuropsychiatry Clin Neurosci* 1994;6:411-418.
10. Salloway S. Diagnosis and treatment of patients with frontal lobe syndromes. *J Neuropsychiatry and Clin Neurosci* 1994;6:388-398.
11. Coffey CE, Cummings JL, Duffy J, Fink M, Lauterbach EC, Lovell M, Malloy P, Nussbaum P, Royall, DR, Salloway S. Assessment of treatment outcomes in neuropsychiatry. *J Neuropsychiatry and Clin Neurosci* 1995;7:287-289.
12. Salloway S, Malloy P, Rogg J, Kohn R, Duffy J, Tung G, Thomas C, Richardson E, Gillard E, Westlake R. MRI and neuropsychological differences in early and late-life onset geriatric depression. *Neurology* 1996;46:1567-1574.
13. Salloway S. Clinical-Pathological Case Conference: Depression, behavior change and subcortical dementia in a 57-year-old woman. A case of biopsy-proven CADASIL syndrome. *J Neuropsychiatry and Clin Neurosci* 1996,8:215-221.
14. Salloway S, Cummings J. Subcortical structures and neuropsychiatric disorders. *The Neuroscientist* 1996;2:66-75.
15. Salloway S, Stewart CF, Morales X, Israeli L, Rasmussen S, Brin MF, Blitzler A. Botulinum toxin for refractory vocal tics. *Movement Disorders* 1996;11: 746-748.
16. Cahn D, Malloy P, Salloway S, Rogg J, Kohn R, Gillard E, Tung G, Richardson E. Subcortical hyperintensities on magnetic resonance imaging and activities of daily living in geriatric depression. *J Neuropsychiatry and Clin Neurosci* 1996;8:404-411.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

17. Jenkins M, Salloway S, Westlake R. The diagnosis and treatment of geriatric depression. *Journal of Practical Psychiatry and Behavioral Health* 1996;6:336-349.
18. Salloway S, Mermel LA, Aspinall GO, Mam Shin JE, Kurjanczyk LA, Seamans M, Penner JL. Miller Fisher Syndrome associated with *Campylobacter* Jejuni bearing lipopolysaccharide molecules mimicking human ganglioside GD 3. *Infection and Immunity* 1996;64:2945-2949.
19. Harrington C, Salloway S, Malloy P. Dramatic neurobehavioral disorder in two cases following anteromedial frontal lobe injury: delayed psychosis and marked change in personality. *Neurocase* 1997;3:137-149.
20. Jenkins M, Cimino C, Malloy P, Salloway S, Cohen R, Kohn R, Westlake R. Neuropsychiatric factors in the illusion of visitors among geriatric patients: a case series. *J Geriatric Psychiatry and Neurology* 1997;10:79-87.
21. Salloway S, White J. Paroxysmal limbic disorders in neuropsychiatry. *J Neuropsychiatry Clin Neurosci* 1997;9:493-509.
22. Mega M, Cummings C, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. *J Neuropsych Clin Neurosci* 1997;9:405-420.
23. Jenkins M, Cohen R, Malloy P, Salloway S, Gillard E, Penn J, Neeper R. Neuropsychology measures discriminate among adults with residual ADD and other attentional complaints. *The Clinical Neuropsychologist*, 1998;12:74-83.
24. Jenkins M, Malloy P, Salloway S, Cohen R, Gillard E, Kohn R, Rogg J, Tung G. Frontal-subcortical contributions to memory: Evidence from geriatric depressed patients with subcortical hyperintensities on MRI. *Journal of Neuroimaging* 1998, 8:20-26.
25. Kleiner-Fisman GK, Salloway S, Fisman SN. Recollection of childhood sexual abuse following endotracheal intubation. *Psychosomatics* 1998;39:561-2.
26. Cohen R, Kaplan R, Zuffante P, Moser D, Jenkins M, Salloway S, Wilkinson H. Alteration of intention and self-initiated action associated with bilateral anterior cingulotomy. *J Neuropsych Clin Neurosci* 1999;11:444-453.
27. Cahn-Weiner D, Malloy P, Boyle P, Marran M, Salloway S. Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals. *The Clinical Neuropsychologist* 2000; 14:187-195.
28. Norton L, Malloy PF, Salloway S. The impact of behavioral symptomatology on activities of daily living in patients with dementia. *Am J Geriatr Psych* 2001;9:1-8.
29. Salloway S, Boyle P, Correia S, Malloy P, Cahn-Weiner D, Schneider L, K. Krishnan R, Nakra R. The relationship of MRI subcortical hyperintensities to treatment response in a placebo-controlled trial of sertraline in geriatric depressed outpatients. *Am J Ger Psych*, 2002;10:107-111.
30. Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Tavares R, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. *J Neurological Sciences* 2002;203-204:183-187.
31. Salloway S, Correia S, Boyle P, Malloy P, Schneider L, Lavretsky H, Sackheim H, Roose S, Krishnan KRR. MRI subcortical hyperintensities in old and very-old depressed outpatients: the important role of age in late-life depression. *J Neurological Sciences* 2002;203-4:227-233.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

32. Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance and caregiver burden in Alzheimer's disease. *Alzheimer's Disease and Associated Disorders* 2002, Oct-Dec;16(4):248-53.
33. Boyle P, Malloy P, Salloway S, Cummings J. Executive dysfunction and apathy predict functional impairment in Alzheimer's disease. *Am J Ger Psych* 2003;11:214-221.
34. Black S, Roman G, Geldmacher D, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled trial. *Stroke* 2003;34:2323-2332.
35. Malloy P, Belanger H, Hall S, Aloia M, Salloway S. Assessing visuoconstructional performance in AD, MCI and normal elderly using the Berry Visual-Motor Integration Test. *The Clinical Neuropsychologist*, 2003;17:544-550.
36. Salloway S, Stopa S, Douglas F, Wilterdink J, Rogg J. Amyloid angiopathy associated with cerebral hemorrhage, extensive microhemorrhages and fluctuating leukoencephalopathy. *J Neurological Sciences* 2005, in press.
37. Salloway S, Ferris S, Kluger A, Goldman T, Griesing T, Kumar D, Richardson S. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial, *Neurology* 2004;63:651-657.
38. Belanger H, Wilder-Willis K, Malloy P, Hamman R, Salloway S, Grigsby J. Assessing motor and cognitive regulation in Alzheimer's disease, mild cognitive impairment and normal elderly using the behavioral dyscontrol scale. *Archives of Clinical Neuropsychology* 2005;20:183-189.
39. Maclean A, Correia S, Woods R, Stopa E, Cortez S, Alderson L, Salloway S. Spontaneous lobar hemorrhage in CADASIL. *J Neurology Neurosurgery and Psychiatry* 2005;76:456-7.
40. Roman G, Wilkinson D, Doody R, Black S, Salloway S, Schindler R. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. *Dementia and Geriatric Cognitive Disorders*, 2005,20:338-344.
41. Steffens D, Otey E; Alexopoulos G; Butters M; Cuthbert B; Ganguli M; Geda Y; Hendrie H; Krishnan R, Kumar A; Lopez O; Lyketsos C; Mast B; Morris J; Norton C; Peavy G; Petersen R; Reynolds C; Salloway S; Welsh-Bohmer K; Yesavage J. Perspectives on depression, mild cognitive impairment, and cognitive decline. *Arch Gen Psychiatry* 2006;63:130-138.
42. Grundman M, Petersen R, Bennett D, Feldman H, Salloway S, Jelle-Visser P, Thal L, Schenk D, Khachaturian Z, Thies W, for the Alzheimer's Association Research Roundtable. Alzheimer Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? *Alzheimer's and Dementia* 2006, in press.
43. Salloway S, Correia S, Richardson S. Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnesic MCI. *Int Psychogeriatrics* 2008;20:40-46.
44. Greenberg BD, Malone DA, Rezai AR, Friehs GM, Kubu CS, Malloy PF, Salloway SP, Machado AG, Okun MS, Goodman WK, Rasmussen SA. Three year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder: *Neuropsychopharmacology* 2006;31:2384-93.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

45. Fillit H, Doody RS, Binaso K, Crooks G, Ferris S, Farlow M, Leifer B, Mills C, Minkoff N, Orland B, Reichman W, Salloway S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. *Am J Geriatric Pharmacother* 2006;4 Suppl A:S9-S24.
46. Salloway S. Buying time: Management of mild cognitive impairment and early dementia. *Int Psychogeriatr*. 2006 Sep;18 Suppl 1:S17-23.
47. Laidlaw DH, Lee SY, Correia S, Tate DF, Paul RH, Zhang S, Salloway SP, Malloy PF. Quantitative tract-of-interest metrics for white matter integrity based on diffusion tensor MRI data. *Views Radiology* 2007;8:2-4.
48. Cohen R, Butala P, Salloway S, Gonzalez L, Johansen C, Tovares R, Hovanesian V, Hulette C, Vitek M, Stopa E. Cerebral arteriolar angiopathy, Braak Stage, vascular β -amyloid and APOE genotype, *Stroke* 2008;39:in press.
49. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. *Neurology* 2007;69:448-458.
50. Dubois B, Feldman H, Jacova C, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, Morris J, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser P, Scheltens P. Research criteria for diagnosing Alzheimer's disease: Revising the NINCDS-ADRDA Criteria. *Lancet Neurology* 2007;6:734-746.
51. Salloway S, Mintzer J, Weiner M, Cummings J. Disease modifying therapies for Alzheimer's disease, *Alzheimer's and Dementia*;2008,4:65-79.
52. Dichgans M, Markus H, Salloway S, Verkkoniemi A, Wang Q, Moline M, Posner H, Chabriat H. Donepezil in subcortical vascular cognitive impairment: a randomized double blind trial in CADASIL. *Lancet Neurology* 2008, in press.
53. Salloway S, Correia S. One hundred years of Alzheimer's disease: Time to improve diagnosis and treatment in primary care. *Cleveland Clinic Journal of Medicine*; 2008, in press.
54. Malone D, Greenberg B, Salloway S. Deep Brain Stimulation of the Ventral Internal Capsule/Ventral Striatum for Obsessive-Compulsive Disorder: Worldwide Experience. *Molecular Psychiatry* 2008, in press.
55. Correia S, Lee S, Tate D, Paul R, Zhang S, Salloway S, Malloy P, Laidlaw D. Quantitative tractography metrics for white matter integrity based on diffusion tensor MRI data. *Neuroimage* 2008, in press.

OTHER PEER-REVIEWED PUBLICATIONS:

1. Salloway S, Malloy P, Duffy J. The frontal lobes and neuropsychiatric illness. *J Neuropsychiatry Clin Neurosci* 1994;6:341-2.
2. Salloway S, Daly J. The neurochemistry of Alzheimer's disease. In: Richter R, ed. *Alzheimer's disease: A guide to clinical management*. New York, Mosby Press, 1996; 256-284. (Book Chapter)

Curriculum Vitae:

Stephen P. Salloway, MD, MS

3. Greenblatt S, Salloway S. Clinical examination of cognitive functions. In: Wilkins RH, Rengachary SS, eds. *Neurosurgery* 2nd ed. New York, McGraw-Hill 1996;49-58. (Book Chapter)
4. Saver J, Salloway S, Bear D, Devinsky O. Neuropsychiatry of aggression. In: Fogel B, Schiffer R, Rao S, eds. *Neuropsychiatry*. Baltimore, Williams and Wilkins 1996;523-548. (Book Chapter)
5. Cohen R, Salloway S. Disorders of attention In: Yudofsky S, Hales R, eds. *Textbook of Neuropsychiatry*. 3rd edition. Washington D.C., American Psychiatric Press 1997:413-446. (Book Chapter)
6. Mega M, Cummings J, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic and clinical perspective, In: *The Neuropsychiatry of Limbic and Subcortical Disorders*, Salloway S, Malloy P, Cummings J. Washington, D.C., American Psychiatric Press, 1997, 3-18. (Book Chapter)
7. Salloway S, White J. Paroxysmal limbic disorders in neuropsychiatry, In: *The Neuropsychiatry of Limbic and Subcortical Disorders*, Salloway S, Malloy P, Cummings J. Washington, D.C., American Psychiatric Press, 1997, 95-112. (Book Chapter)
8. Malloy PM, Cummings JL, Coffey CE, Duffy J, Fink M, Lauterbach EC, Lovell M, Nussbaum P, Royall, DR, Salloway S. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. *J Neuropsych Clin Neurosci* 1997;9:189-197.
9. Cummings JL, Coffey CE, Lauterbach EC, Lovell M, Malloy P, Royall, DR, Rummans TA, Salloway S. The clinician-scientist in neuropsychiatry: a position statement from the Committee on Research of the American Neuropsychiatric Association. *J Neuropsych Clin Neurosci* 1998; 10:1-9.
10. Lauterbach E, Cummings J, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans TA, Salloway S. Neuropsychiatric correlates and treatment of lenticulo-striatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. *J Neuropsych Clin Neurosci* 1998; 10:249-266.
11. Salloway S, Hong J. The CADASIL Syndrome: a genetic form of vascular dementia. *J Geriatric Psychiatry and Neurology* 1998;11:71-77.
12. Rummans T, Lauterbach E, Coffey E, Royall D, Cummings J, Salloway S, Duffy J, Kaufer D. Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled trials. *J Neuropsych Clin Neurosci* 1999;11:176-189.
13. Salloway S, Harrington R, Orr D, LaFrance C. The diagnosis and treatment of dementia in *Psychiatric Care of the Medical Patient* 2nd edition, Stoudemire A, Fogel B, Greenberg D eds. New York, Oxford Press 1999, 597-620. (Book Chapter)
14. LaFrance C, Lauterbach E, Coffey CE, Salloway S, Kaufer D, Reeve A, Royall D, Aylward E, Rummans T, Lowell M. The use of herbal alternative medicines in neuropsychiatry. *J Neuropsych Clin Neurosci* 2000, 12:177-192.
15. Salloway S. Diagnosis and treatment of frontal lobe syndromes in *The Frontal Lobes and Neuropsychiatric Illness*, Salloway S, Malloy P, Duffy J eds. Washington, D.C., American Psychiatric Press, 2001, 139-152. (Book Chapter)

Curriculum Vitae:

Stephen P. Salloway, MD, MS

16. Campbell J, Duffy J, Salloway S. Treatment strategies for patients with dysexecutive syndromes, in *The Frontal Lobes and Neuropsychiatric Illness*, Salloway S, Malloy P, Duffy J eds. Washington, D.C., American Psychiatric Press, 2001, 153-166. (Book Chapter)
17. Salloway S, Blitz A. Introduction to functional brain circuitry, *Brain Signaling and Circuitry in Psychiatry*, Kaplan G, Hammer R eds., Amer Psychiatric Publishing 2002, Washington, D.C. 1-29. (Book Chapter)
18. Cohen R, Salloway S, Zawacki P. Disorders of attention In: Yudofsky S, Hales R, eds. *Textbook of Neuropsychiatry*. 4th edition. Washington D.C., American Psychiatric Publishing 2002, 489-524. (Book Chapter)
19. Stopa E, Fallon J, Salloway S, et al. Distribution of smooth muscle actin and agrin in the microvascular of the tg app671, 671. Korczyn ed. 2nd International Conference on Vascular Dementia, Monduzzi 2002, 159-163, Bologna.
20. Salloway S, Desbiens S. CADASIL and Other Genetic Causes of Stroke and Vascular Dementia in *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*, Paul R, Cohen R, Ott B, Salloway S eds. Humana Press, Totowa, NJ, 2004,87-98.
21. Salloway S, Harrington C, Jacobson S. Psychiatric evaluation of the neurologic patient, in Friedman JH, Jeste D. eds. *Psychiatry for Neurologists*. Humana Press, Totowa, NJ 2005, 19-32. (Book Chapter)
22. Salloway S. Improving the diagnosis and treatment of Alzheimer's disease. *Medicine and Health Rhode Island* 2006, 89;5:12-14.
23. Salloway S. Cholinergic treatment across the spectrum: therapeutic trends in mild to severe dementia. *Int Psychogeriatr*. 2006 Sep;18 Suppl 1:S1-2.
24. Cohen R, Salloway S, Sweet L. Neuropsychiatric aspects of disorders of attention In: Yudofsky S, Hales R, eds. *The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences*, 5th edition. Washington D.C., American Psychiatric Publishing 2007, 485-529. (Book Chapter)
25. Salloway S, Brennan-Krohn T, Correia S, Mellion M, delaMonte S. CADASIL: a genetic model of arterial degeneration, white matter injury and dementia. In *Neurobehavior of Dementia*, Miller B and Boeve B eds. Cambridge University Press, Cambridge, UK, 2007, in press.
26. Salloway S. Taking the Next Steps in the Treatment of AD: Disease-Modifying Agents. *CNS Spectrums* 2008;13, suppl 3:11-14.
27. Salloway S. The Prevalence of Alzheimer's Disease: A Growing Crisis, *CNS Spectrums* 2008;13, suppl 3:3.

BOOKS

1. Salloway S, Malloy P, Cummings J. *The Neuropsychiatry of Limbic and Subcortical Disorders*. American Psychiatric Press Inc., Washington, D.C. 1997.
2. Salloway S, Malloy P, Duffy J. *The Frontal Lobes and Neuropsychiatric Illness*. American Psychiatric Press Inc., Washington, D.C., 2001.
3. Paul R, Cohen R, Ott B, Salloway S eds., *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*, Humana Press, Totowa, NJ, 2004.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

OTHER NON- PEER REVIEWED PUBLICATIONS:

1. Salloway S. Book review of Neurology for the Psychiatry Specialty Board Review, Weisberg L, *Psychiatric Times* Nov. 1992;44 (Book Review)
2. Salloway S, Duffy J. Neuropsychiatric aspects of depression. *Rhode Island Medicine* 1993; 76:425-430 (invited).
3. Salloway S. Neuropsychiatric aspects of movement disorders. *Rhode Island Medicine* 1993; 76:549-552 (invited).
4. Salloway S, Fowkes V. Behavioral Science in Primary Care, a teaching manual, Stanford Press, 1985.
5. Salloway S, Clinical neuroanatomy and neurochemistry for psychiatrists. In: Kaufman D., Editor, *Clinical Neurology for Psychiatrists*, Albert Einstein Press, 1991.
6. Salloway S, Faber R. Highlights of the Fifth Annual Meeting of the American Neuropsychiatric Association. *J Neuropsychiatry and Clinical Neurosci* 1993;5:442-3.
7. Salloway S. Review of Epilepsy and the Quality of Life. Trimble M, Dodson W. Raven Press 1995 in *Am J Psychiatry* 1996;153:4 (Book Review)
8. Salloway S. Review of Brain Activation. Roland P, Wiley Liss 1993 in *J Neuropsychiatry and Clin Neurosci* 1996 (Book Review)
9. Salloway S. CADASIL: A new disease causing subcortical dementia and depression. *Psychiatric Times*, 1997;14:8-9.
10. Harrington C, Salloway S. The diagnosis and treatment of post-stroke depression. *Rhode Island Medicine* 1997;80:181-187.(invited).
11. Salloway S. The nucleus accumbens: a key structure mediating substance abuse and reward. *Psychiatric Times*, 1998; 15:62-4.
12. Salloway S. Clinical applications of brain SPECT scanning in neurology and psychiatry. *Psychiatric Times* 1999; 16:72-74.
13. Heindel W, Salloway S. Memory Systems in the Human Brain. *Psychiatric Times* 1999;16:19-21.
14. Salloway S. The CADASIL syndrome:a genetic cause of small vessel stroke and dementia. *Neurology Network Commentary* 1999;3:40-45.
15. Cahn-Weiner D, Salloway S. Diagnosis and treatment of mild cognitive impairment. *Psychiatric Times* 1999, 9:24-26.
16. Rymer S, Salloway S. Hidden victims of Alzheimer's disease. *Psychiatric Times* 2000;17:44-51.
17. Salloway S. Advances in clinical neuroscience from the AAN 53rd Annual Meeting. *Psychiatric Times*, 2001;9:1,10 and 11.
18. Salloway S, Correia S, Peck J, Harrington C. Dementia with Lewy Bodies: A Diagnostic and Treatment Challenge. *RI Medicine* 2002;85(7):207-9.
19. Salloway S. New monoclonal antibody aids diagnosis of CADASIL. *Journal Watch Neurology* 2002;4:20.
20. Salloway S. Features of frontotemporal dementia-3. *Journal Watch Neurology* 2003;5:9.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

21. Salloway S. Advances in the treatment of dementia. *The Clinical Advisor*, 2003, in press.
22. Salloway S. Does social isolation influence outcomes after stroke? *Journal Watch Neurology* 2006;8:28.
23. Salloway S. Cholinergic treatment across the spectrum of Alzheimer's disease (Guest Editorial). *Int Psychogeriatrics*, in press, 2006.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

None

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. Roman G, Royall D, Scheltens P, Doody R, Salloway S, Black S, Kumar, D, Schindler R, Posner H. Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind, randomized, placebo-controlled trial in vascular dementia patients, in preparation.
2. Malone D, Dougherty D, Rezai A, Carpenter L, Friehs G, Eskander E, Rauch S, Rasmussen S, Machado A, Kubu C, Tyrka A, Price L, Stypulkowski P, Giftakis J, Malloy P, Salloway S, Greenberg B. Long-term outcome of deep brain stimulation for highly resistant depression. Submitted to *Biological Psychiatry*.
3. Doody RS, Ferris S, Salloway S, Murthy A, Li MC, Goldman R. Inter-rater reliability between expert and non-expert physicians in the diagnosis of amnesic MCI in the community setting.
4. Doody RS, Ferris S, Salloway S, Murthy A, Goldman R, Xu Y, Sun Y. Donepezil treatment of patients with MCI: a 48 week randomized, placebo-controlled trial.
5. Salloway S, Malloy P, Correia S. A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: a subanalysis of two 24-week, randomized double-blind, placebo-controlled trials, in preparation.
6. Salloway S, Correia S, Malloy P, Nassery S. Ambulatory blood pressure monitoring in Alzheimer's patients with high and low levels of MRI subcortical hyperintensities, in preparation.
7. Salloway S, Roman G, Correia S, Malloy P. Critical review of the NINDS-AIREN criteria for vascular dementia, in preparation.
8. Salloway S, Krishnan R, Sackheim H, Roose S. Role of MRI subcortical hyperintensities in the treatment response to citalopram in outpatients 75 and older with major depression, in preparation.

ABSTRACTS

1. Campbell J, Duffy J, Salloway S. Apathy and Memory Loss following bilateral anteromedial thalamic infarctions. *J Neuropsychiatry and Clin Neurosci* 1993; 5:446.
2. Salloway S, Malloy P, Rogg J, Duffy J, Kohn R, Richardson E, Gillard E, Thomas C. Subcortical MRI changes in late-life onset depression. *J Neuropsychiatry and Clin Neurosci* 1993; 5:446-447.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

3. Campbell J, Salloway S, Duffy J, Malloy P. Utilization behavior and disinhibition in an 82 year old woman. *J Neuropsychiatry and Clin Neurosci* 1994;7:298.
4. Malloy P, Salloway S. Reduplicative paramnesia following lacunar infarction of the right genu of the internal capsule. *J Neuropsychiatry and Clinical Neurosci* 1994;7:317.
5. Salloway S, Dammers P, Eveloff S. REM Sleep Behavior Disorder associated with a cingulate lesion. *J Neuropsychiatry and Clinical Neurosci* 1994; 7:298.
6. Salloway S, Rasmussen S, Brin M, Blitzer A. Laryngeal botulinum toxin injection for refractory vocal tics. *J Neuropsychiatry and Clinical Neurosci* 1994;7:298-299.
7. Salloway S, Malloy P, Rogg J, Duffy J, Kohn R, Thomas C, Richardson E. Clinical significance of subcortical encephalomalacia in early and late onset depression. *Neurology* 1994;44 suppl 2:A375.
8. Salloway S, Rasmussen S, Malloy P. Resolution of longstanding obsessive compulsive disorder following left anteromedial thalamic infarction. *Neurology* 1995;45(suppl 4):A167.
9. Salloway S, Malloy P, Rogg J, Thomas C, Lan J. Neuroimaging Tutorial: A Practical Guide for the Clinician. Accepted for Presentation at the 1995 American Academy of Neurology Annual Meeting but unpublished.
10. Malloy P, Morales X, Salloway S, Richardson E. Sexual delusions: A case series. *J Neuropsychiatry and Clin Neurosci* 1995;7:405.
11. Jenkins M, Malloy P, Salloway S, Biber M. Aphasia and delusions as primary symptoms in a case of multiple sclerosis. *J Neuropsychiatry and Clin Neurosci* 1995;7:404.
12. Chang K, Neeper R, Jenkins M, Penn J, Bollivar L, Israeli L, Malloy P, Salloway S. Clinical profile of patients referred for evaluation of adult attention deficit hyperactivity disorder. *J Neuropsychiatry and Clin Neurosci* 1995;7:400-401. (American Neuropsychiatric Association Young Investigator Award Honorable Mention).
13. Cahn DA, Malloy P, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED. Subcortical hyperintensities on magnetic resonance imaging and activities of daily living in geriatric depression. *Archives of Clinical Neuropsychology* 1995;11:374. (Presented at the 15th Annual Meeting of the National Academy of Neuropsychology)
14. Jenkins M, Salloway S, Malloy P, Rogg J, Kohn R, Tung G, Richardson E, Gillard E. Frontal subcortical contributions to memory in depressed geriatric patients with periventricular hyperintensities on MRI. *Neurology* 1996;46:A432.
15. Salloway S, Stopa E. Subcortical dementia and depression in biopsy-proven CADASIL: pathological and radiological findings. *Neurology* 1996;46:A326.
16. Jenkins M, Malloy P, Cohen R, Salloway S, Neeper R, Penn J, Chang K. Attentional and learning dysfunction among adults with history of childhood ADHD. *J International Neuropsychological Society* 1996;2:209. Presented at International Neuropsychological Society 19th Annual Mid-Year Meeting, Veldhoven, The Netherlands, June 1996.
17. Cohen R, Aloia M, Holler K, Jenkins M, Malloy P, Gordon N, Stone W, Salloway S. Quantitative MRI ratings of subcortical leukoaraiosis in the assessment of dementia: reliability and clinical correlation. *J Neuropsychiatry and Clin Neurosci* 1997;9:134.
18. Westlake R, Jenkins M, Malloy P, Salloway S, Kohn R, Luketela K. Clinical significance of white matter hyperintensities on MRI in geriatric depression. Proceedings of the American

Curriculum Vitae:

Stephen P. Salloway, MD, MS

- Psychiatric Association 1997 Annual Meeting, p. 250. Poster Presentation in New Research Proceedings of the 1997 American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
19. Jenkins M, Malloy P, Salloway S, Kohn R, Westlake R, Javorsky D. Apathy and activities of daily living in geriatric depressed patients with and without CT scan-identified white matter disease. Proceedings of the American Psychiatric Association 1997 Annual Meeting, p. 249. Poster Presentation in New Research Proceedings of the 1997 American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
 20. Abuelo D, Salloway S. Presymptomatic diagnosis of CADASIL. Proceedings of the American College of Medical Genetics 4th Annual Meeting and the 28th Annual Meeting of the March of Dimes Clinical Genetics Conference. Feb 1997, Ft. Lauderdale, Florida, p. A32.
 21. Intal J, Salloway S, Stopa E, Donohue J. MRI-autopsy correlation of signal hyperintensities in leukoencephalopathy. Society of Neuroscience Abstracts 1997, 833. Presented at the 27th Annual Meeting of the Society for Neuroscience, New Orleans.
 22. Jenkins M, Hong J, Salloway S, Malloy P, Rickler K, Cohen R. Improvement in attention with stimulant treatment in adults with ADHD. *J Neuropsychiatry Clin Neurosci* 1997, 9:649. Presented at the 9th Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1998.
 23. Tremont G, Stern R, Abuelo D, Geffroy G, Walsh A, Salloway S. Early-onset dementia in a mentally retarded adult associated with novel presenilin-I mutations. *J Neuropsychiatry Clin Neurosci* 1997, 9:697. Presented at the 9th Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1998.
 24. Salloway S, Jenkins M, Intal J, Javorsky D, Malloy P. FLAIR is more sensitive than proton density weighting for visualizing and measuring SH in geriatric hypertension. *J Neuropsych Clin Neurosci* 1999; 11:155. Presented at the 10th Annual Meeting of the American Neuropsychiatric Association in New Orleans, LA.
 25. Salloway S, Mega M. The neuropsychiatry of limbic and subcortical disorders. Proceedings of the Third International Neuropsychiatry Congress. Kyoto, Japan, April 2000.
 26. Jenkins M, Salloway S, Malloy P, Hong J, McKiernan K. Effects of stimulant treatment for adult ADHD on executive functioning. *J Neuropsych Clin Neurosci* 2001;13:133. Presented at the 12th Annual Meeting of the American Neuropsychiatric Association, Ft. Myers, FL.
 27. LaFrance C, Salloway S, Greenberg B. Obsessive Compulsive Symptoms, Mood and Laterality in Patients with Spasmodic Torticollis. *Movement Disorders* 2001;16(Sup 1):S48. Presented at the First International Congress of Behavioral Dysfunction in Movement Disorders October 2001, Montreal, Canada.
 28. Stopa E, Fallon J, Salloway S, Butala P, Zipser B, Morales X, Hovanessian V, Hulette C, Rosenberg C, Tavares R, Johanson C, Vitek M. Differential distribution of smooth muscle actin and agrin in the microvasculature of the tg app670, 671 mouse and alzheimer brain.. Society of Neuroscience Abstracts 2001, in press. Presented at the 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2001.
 29. Salloway S, Stopa E, Douglas F, Wilterdink J, Rogg J. Amyloid angiopathy associated with cerebral hemorrhage, extensive microhemorrhages and severe white matter edema. Presented at the 2nd International Conference on Vascular Dementia, January 2002, Salzburg, Austria.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

30. Salloway S, Boyle P, Malloy P, Correia S, Krishnan R, Schneider L, Cahn-Weiner D, Nakra R. MRI subcortical hyperintensities in outpatient geriatric major depression: information from two recent randomized, prospective placebo controlled trials. Presented at the 2nd International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
31. Gur T, Stopa E, Fallon J, Salloway S. Effect of APOE4 genotype on capillary basement membrane area in Alzheimer's disease. Presented at the 2nd International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
32. Boyle P, Malloy P, Salloway S. Frontal lobe function and the predictors of functional abilities in patients with dementia. *JINS* 2001;7(4):486. Presented at the Annual Meeting of the International Neuropsychological Association, February 2001, Chicago, IL.
33. MacLean, A, Salloway S, Woods R, Stopa E, Douglas F, Wilterdink J, Rogg J. Novel findings in two cases of biopsy-proven small artery disease: Spontaneous cerebral hemorrhage in CADASIL and severe white matter edema in amyloid angiopathy. *Neurobiology of Aging* 2002;23(1S):S172. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden
34. Salloway S, Pratt RD, Perdomo CA and The Donepezil 308 VaD Study Group. Donepezil treated patients with vascular dementia demonstrate cognitive and global benefits. *Neurobiology of Aging* 2002;23(1S):S57. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
35. Malloy P, Rymer S, Salloway S, Lauren Norton. Contributions to caregiver burden in Alzheimer's disease: awareness of deficit and behavioral disturbance. *Neurobiology of Aging* 2002;23(1S):S159. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
36. Correia S, Salloway S, Boyle P, Malloy P, Cahn-Weiner D, Scheider L, Krishnan RR, Nakra R. Relationship of subcortical hyperintensities to treatment response in young and old elderly with outpatient geriatric depression: Results of two placebo-controlled trials. *Neurobiology of Aging* 2002;23(1S):S159. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
37. Boyle P, Malloy P, Salloway S, Correia S. Functional significance of subcortical white matter changes in Alzheimer's disease. *Neurobiology of Aging* 2002;23(1S):S495. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
38. Salloway S, Gustavo Roman G. Critical review of the NINDS-AIRENS Vascular Dementia Criteria. Presented at the Alzheimer's Imaging Consortium, July 2002, Stockholm, Sweden.
39. Salloway S, Pratt R, Perdomo CA. Donepezil improves cognition in patients with probable and in those with possible vascular dementia. *Eur J Neurol* 2002;9(suppl 2):192(p3114). Presented at the European Federation of Neurological Societies, October 2002, Vienna, Austria.
40. Salloway S, Pratt R, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia and Alzheimer's disease. Presented at the European Federation of Neurological Societies, October 2002, Vienna, Austria.
41. Salloway S, Richardson S, Ferris S, Kluger A. Benefits of donepezil treatment in patients with mild cognitive impairment. American Academy of Neurology 55th Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A411-2

Curriculum Vitae:

Stephen P. Salloway, MD, MS

42. Correia S, Salloway S, Roman G. Critical review of the NINDS-AIREN criteria for vascular dementia. American Academy of Neurology 55th Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A377-8.
43. Salloway S, Malloy P, Correia S. A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: a subanalysis of two 24-week, randomized double-blind, placebo-controlled trials. American Academy of Neurology 55th Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A141-2.
44. Salloway S, Richardson S. Donepezil treatment provides benefits in patients with mild cognitive impairment. International Psychogeriatric Association 11th International Congress, Chicago, August, 2003, *International Psychogeriatrics* 2003;15, suppl 2:107.
45. Correia S, Salloway S, Belanger H, Nassery S, Malloy P, Drodge S. Ambulatory blood pressure monitoring in Alzheimer's disease patients with high and low degree of subcortical hyperintensities. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003. *J Neurol Sci* 2004;226:150-1.
46. Salloway S, Pratt RD, Perdomo CA. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003. *J Neurol Sci* 2004;226:160-161.
47. Miaux Y, Guermazi A, Salloway S, Sieffert M, Altman H, Pratt R. Neuroradiological Features Associated with Vascular Dementia. European Society of Neuroradiology. Istanbul Turkey, September 2003.
48. Guermazi A, Miaux Y, Sieffert M, Salloway S, Altman, Pratt R. Neuroradiological findings in vascular dementia. Radiological Society of North America 89th Annual Meeting, Chicago November 2003.
49. Tremont G, Davis J, Slavin C, Bishop D, Salloway S. Family Functioning as a Predictor of Burden in Caregivers of Patients with Mild to Moderate Dementia. International Neuropsychological Association 32nd Annual Meeting Baltimore, MD, February, 2004. *JINS* 2004, in press.
50. Salloway S, Mahableschwarkar A, Brashear R. Differential efficacy of galantamine in patients with dementia and cerebrovascular disease:a subanalysis by CVD lesion subtypes. Presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 2003.
51. Wilder-Willis, KE, Malloy, PF, Salloway, S, Correia, S, Belanger, HG, Kumariah, D, Flynn-O'Brien, K. Performance on the delayed response and delayed matching to sample task in patients with mild cognitive impairment and healthy elderly controls. International Neuropsychological Association 32nd Annual Meeting Baltimore, MD, February 2004. *JINS* 2004, in press.
52. Salloway S, Ieni J, Griesing T, Goldman R, Kluger A, Kumar D, Richardson S. Cognitive response in patients with amnesic mild cognitive impairment: benefits of donepezil. American Association of Geriatric Psychiatry 17th Annual Meeting, February, 2004 Baltimore, MD.
53. Laidlaw, DH, Zhang S, Bastin ME, Correia S, Salloway S, Malloy P. Ramifications of isotropic sampling and acquisition orientation on DTI analyses. International Society of Magnetic Resonance in Medicine, Tokyo, Japan, May 2004.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

54. Auchus A, Brashear HR, Salloway S, Scheltens P, Korczyn A, Gassman-Mayer C, Gold M. Results of a trial of galantamine subjects with vascular dementia confirmed by a central reading. *Neurology* 2004; American Academy of Neurology Annual Meeting, San Francisco, CA, April 2004.
55. Davis J, Tremont G, Slavin C, Salloway S. Caregiver perception of executive dysfunction and behavioral problems as predictors of burden in dementia caregivers. *Journal of Neuropsychiatry and Clinical Neurosciences*. in press; Paper presented at the 2004 Meeting of the American Neuropsychiatric Association, Bal Harbour, FL
56. Correia S, Zhang S, Laidlaw D Malloy P, Salloway S. (2004) Diffusion-tensor imaging: linear, planar, and spherical diffusion in CADASIL. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, Philadelphia. Abstract P2-232 *Neurobiology of Aging* 2004;25(S2):S298.
57. Correia S, Salloway S, Malloy P, Song C, Li R. (2004) Systolic Blood Pressure Variability and Subcortical Hyperintensities in Patients with Mild-To-Moderate Alzheimer's Disease. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, Philadelphia. *Neurobiology of Aging* 2004;25(S2):S278
58. Malloy PF, Belanger H, Hall S, Grigsby J, Hamman RF, Wilder-Willis K, Aloia M, Salloway S. Validation of Measures of Spatial and Executive Abilities in Alzheimer's Disease and Mild Cognitive Impairment. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17-22, 2004. *Neurobiology of Aging* 2004; 25(S2): S112.
59. Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Donahue JE, Hulette CM, Vitek MP, Stopa EG. Microvascular Damage in Alzheimer's disease. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17-22, 2004. *Neurobiology of Aging* 2004; 25(S2): S408.
60. Salloway S, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12-18 months maintain cognitive benefits. Presented at the 8th Congress of the European Federation of Neurological Societies. Paris, France, September, 2004. *European Journal of Neurology* 2004;11 suppl 2,184.
61. Correia S, Brennan-Krohn T, Zhang S, Laidlaw D, Malloy P, Salloway S. Diffusion-Tensor Imaging and Executive Function in Subcortical Ischemic Vascular Disease and Mild Cognitive Impairment. Presented at the International Neuropsychological Association 33nd Annual Meeting St. Louis, MO, February 2005. *JINS* 2005, in press.
62. Salloway S, Ferris S, Kluger A, Goldman T, Griesing T, Kumar D, Richardson S. Key lessons learned from the design and outcome of a 24 week donepezil mild cognitive impairment trial. Cold Spring Harbor Laboratory Mechanisms of Drug Discovery in Neurodegenerative Disorders Conference, Cold Spring Harbor, NY, December, 2004.
63. Brennan-Krohn T, Dong M, Rivera E, Salloway S, delaMonte S,. CADASIL: Molecular Analysis of Aberrant Gene Expression in the Brain. Presented at the NIMH Summer Training in Aging Research Topics Mental Health Annual Conference, San Diego, CA, August, 2005.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

64. Correia S, Lee S, Malloy P, Mehta N, Zhang S, Salloway S, Laidlaw DH. Diffusion-Tensor MRI Tractography Methods For Assessing White Matter Health And Its Relationship To Cognitive Functioning. International Neuropsychological Society 34th Annual Meeting, Boston, February 2006
65. Lee SY, Correia S, Tate DF, Paul RF, Zhang S, Salloway SP, Malloy PF, and Laidlaw DH. Quantitative Tract-of-Interest Metrics for White Matter Integrity Based on Diffusion Tensor MRI Data. Oral Presentation. 14th International Society for Magnetic Resonance in Medicine Scientific Meeting & Exhibition, Seattle, Washington, May 2006
66. Vascular Dementia and Vascular Cognitive Impairment: Treatment Approaches. Brain and Cognition 2006, in press.
67. Correia S, Lee S, Zhang S, Salloway SP, Malloy PF, Laidlaw DH. Diffusion-tensor imaging tractography: correlation with processing speed in aging. Alzheimer's and Dementia 2006;Vol 2,#3:S317-8, S686. Presented at the *10th International Conference on Alzheimer's Disease and Related Disorders (ICAD) (Best Poster Award)*. Madrid, Spain, July, 2006.
68. Brennan-Krohn T, Dong M, Rivala E, Salloway S, delaMonte S. CADASIL: Molecular Analysis of Aberrant Gene Expression in the Brain. Alzheimer's and Dementia 2006;Vol 2,#3:S564-5. Presented at the *10th International Conference on Alzheimer's Disease and Related Disorders (ICAD)*. Madrid, Spain, July, 2006.
69. Davis C, Salloway S, Doody R, McRae T, Kumar D, Posner H, Surick I. Safety findings from the donepezil vascular dementia program. Alzheimer's and Dementia 2006;Vol 2,#3 in press. Presented at the *10th International Conference on Alzheimer's Disease and Related Disorders (ICAD)*. Madrid, Spain, July, 2006.
70. Patel K., Correia S, Foley J, Schlicting E, Zhang S, Laidlaw D, Salloway S. Cognitive impairment, hippocampal volume, and white matter integrity in CADASIL. 35th Meeting of the International Neuropsychological Society, Portland OR, February 7-10, 2007.
71. Schlicting E, Correia S, Malloy P, Salloway S. N-back performance and standardized measures of processing speed, executive function, and working memory in mild cognitive impairment vs. normal controls. 35th Meeting of the International Neuropsychological Society, Portland OR, February 7-10, 2007.
72. Brennan-Krohn T, Dong M, Rivala E, Salloway S, delaMonte S. Aberrant Gene Expression in the Brain in CADASIL. Neurology 2007, in press. Presented at the 59th Annual Meeting of the American Academy of Neurology, Boston, MA, May, 2007.
73. Correia S, Foley J, Zhang S, Laidlaw D, Malloy P, Salloway S. Processing speed in CADASIL: Relationship to cingulum vs. callosal fibers. Presented at the Third Congress of the International Society for Vascular Cognitive and Behavioral Disorders, San Antonio, Texas, July, 2007.
74. Patel K, Correia S, Epstein S, Schlicting S, Zhang S, Laidlaw D, Malloy P, Salloway S. Grey and white matter changes on MRI and diffusion-tensor imaging and cognitive function in mild cognitive impairment. (2008). Paper presentation. 36th Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

75. Song S, Correia S, Schlichting S, Malloy P, Salloway S. Executive impairment and MoCA performance in mild cognitive impairment and Alzheimer's disease (2008). Poster abstract. 36th Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.
76. Schlichting E, Correia S, Malloy P, Salloway S. Classification of patients with amnesic mild cognitive impairment vs. normal controls based on N-back, Self-Ordered Pointing Task, and standardized cognitive measures. Poster abstract. 36th Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008
77. Dichgans M, Markus H, Salloway S, Moline M, Hsu T, Posner H, Hurt S, Wang Q, Chabriat H. Efficacy and tolerability of donepezil in CADASIL: A model of subcortical vascular cognitive impairment. American Heart Association International Stroke Congress, February, 2008.
78. Doody R, Ferris S, Salloway S, Murthy A, Goldman R, Xu Y, Sun Y. A 1 year randomized trial of donepezil in patients with mild cognitive impairment. 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy. Hong Kong, China February, 2008.
79. Salloway S, Dichgans M, Markus H, Moline M, Posner H, Wang Q, Chabriat H. Efficacy and tolerability of donepezil in CADASIL. 60th Annual Meeting of the American Academy of Neurology Late Breaking Science. Chicago, IL, April, 2008.
80. Chabriat H, Markus H, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Dichgans M. Donepezil improves executive function in non-demented CADASIL patients. 17th European Stroke Conference, Nice, France, May, 2008.
81. Salloway S, Dichgans M, Markus H, Moline M, Posner H, Wang Q, Chabriat H. 18 week placebo-controlled trial of donepezil for treatment of cognitive impairment in CADASIL. International Congress of Alzheimer's Disease 2008, Chicago, IL, July, 2008.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA:

Educational Videotapes and CD-ROMs

1. Between a Rock and a Hard Place-Ethical Decision-Making in the Hospital-a training film for medical students. Sachs J Director. Palo Alto, CA, Stanford Video Productions, 1985.
2. Salloway S. Intensive Review of Neurology. Irvine, CA, CME Inc. 1996.
3. Salloway S. Treatment of Fragile Elderly. Houston, TX, American Medical Communications. 1996.
4. Salloway S. Vascular Dementia CD ROM-A Unique Disease Entity or a Variation of Alzheimer's Disease. Innovia Education Institute Columbia, MD, 2003.
5. Salloway S. Advances in the Diagnosis and Treatment of Vascular Dementia in Highlights of the 2nd Annual Dementia Congress: An Interactive CME Activity on CD-ROM, Academy for Health Care Education, New York, New York, 2004.
6. Salloway S. Management of Early Dementia. CD-Pharma Productions, Montreal, CA November, 2005.
7. Salloway S. Advances in Mild Cognitive Impairment and Alzheimer Disease. CD ROM. Clinical Geriatrics/Center for Biomedical Communication Inc., December, 2005.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

8. Salloway S. Diagnosis and Treatment of Mild Cognitive Impairment: Now and in the Future. CD ROM. Highlights of the Fifth Annual Dementia Congress. Academy for Health Care Education Inc., New York, NY, 2007.

INVITED PRESENTATIONS:

1. Sleep and Depression, Clinical Research Unit of the Palo Alto Veterans Hospital, Department of Psychiatry Research Seminar, August 1983
2. Sleep and Aging, Department of Pediatrics Research Conf., Santa Clara Valley Medical Center, January 1984
3. Management of Chronic Pain (Platform), American Psychiatric Association Annual Meeting, Montreal, Canada, May 1988
4. Neuropsychiatric Aspects of Parkinson's Disease and Update on Fetal Cell Transplantation, American Psychiatric Association/NIMH Annual Fall Research Symposium, September 1988
5. Steroid Psychosis, Yale University, Department of Neurology Grand Rounds, September 1989
6. Updates in Neuroradiology with Clinical Correlations, Gaylord Hospital Grand Rounds, Wallingford, CT, March 1990
7. Advances in multiple sclerosis (Platform), Symposium Chair: Updates in Neurology, American Psychiatric Association Annual Meeting, New York, NY, May 1990
8. Practical Neuroanatomy and Neuropharmacology, Gaylord Hospital Grand Rounds, Wallingford, CT, May 1990
9. Movement Disorders, Gaylord Rehabilitation Hospital Grand Rounds, Wallingford, CT, June 1990
10. Delayed-Onset Hypoxic Encephalopathy, Yale University Department of Neurology Grand Rounds, July 1990
11. Yale University Comprehensive Review of Neurology and Psychiatry, Director of a two-day course on clinical neurology, New Haven, CT, September 1990
12. Yale University Comprehensive Review of Neurology and Psychiatry, Director of a two-day course on clinical neurology, New Haven, CT, January 1991
13. Neuropsychiatric Aspects of Movement Disorders, Beth Israel Hospital Behavioral Neurology Grand Rounds, Boston, MA, February 1991
14. Neuropsychiatric Aspects of Movement Disorders, Allegheny Neuropsychiatric Institute Grand Rounds, Pittsburgh, PA, February 1991
15. Neuropsychiatric Aspects of Movement Disorders, Dartmouth University Department of Neurology Grand Rounds, Hanover, NH, February 1991
16. Differentiating Seizures from Pseudoseizures, National Institute of Mental Health Brain Disorders Branch Grand Rounds, Washington, DC, February 1991
17. Topic: Director of a one-day course on clinical neurology, Comprehensive Review of Neurology and Psychiatry, Los Angeles, CA, February 1991
18. Neurotransmitter Systems Relevant to Psychiatry, Clinical Neurology for Psychiatrists, Albert Einstein, New York, NY, March 1991

Curriculum Vitae:

Stephen P. Salloway, MD, MS

19. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, New Orleans, LA, May 1991
20. Yale University Comprehensive Review of Neurology and Psychiatry, New Haven, CT, September 1991
21. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, October 1991
22. Yale University Comprehensive Review of Neurology and Psychiatry, director of a two-day course on clinical neurology, New Haven, CT, January 1992
23. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, February 1992
24. Clinical neurochemistry for psychiatrists, Clinical Neurology for Psychiatrists. Albert Einstein, New York, NY, March 1992
25. Symposium Chairman: The Medial Temporal Lobe and Neuropsychiatric Illness American Psychiatric Association Annual Meeting, Washington, DC, May 1992
26. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, Washington, DC, May 1992
27. Disturbance of memory, space, color and time in a middle-aged artist (Platform), British Neuropsychiatry Association Annual Meeting, Oxford, England, July 1992
28. Advances in Brain Imaging, Department of Psychiatry Grand Rounds, Manchester Memorial Hospital, Manchester, CT, September 1992
29. Yale University Comprehensive Review of Neurology and Psychiatry, director of a two-day course on clinical neurology, New Haven, CT, September 1992
30. Symposium Chairman, The Frontal Lobes and Neuropsychiatric Illness, The Fifth Annual Michael Webb Memorial Symposium, Butler Hospital, Providence, RI, October 1992
31. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, October 1992
32. Practical Neuroimaging for Psychiatrists, US Psychiatric Congress, Chicago, IL, November 1992
33. Movement Disorders: A Video Clinic, US Psychiatric Congress, Chicago, IL, November 1992
34. Sleep Physiology and Neuropsychiatric Aspects of Insomnia, Sleep Disorders: Causes, Assessment and Treatment, VA Hospital, Providence, RI, November 1992
35. Neurobiology of Violent Behavior, National CME conference on Violence and Aggression: A Clinical Update, New Orleans, LA, December 1992
36. Yale-Ochsner Review Course, Clinical Neurology for Psychiatrists, New Orleans, LA, January 1993
37. Intensive Review of Neurology and Psychiatry, Director of a one-day course on clinical neurology, Irvine, CA, February 1993
38. Subcortical MRI changes in late-life onset depression (Platform), American Neuropsychiatric Association Fifth Annual Meeting, San Antonio, TX, March 1993
39. Apathy and memory loss following bilateral anteromedial thalamic infarction (Platform), American Neuropsychiatric Association Fifth Annual Meeting, San Antonio, TX, March 1993

Curriculum Vitae:

Stephen P. Salloway, MD, MS

40. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein, New York, NY, March 1993
41. Symposium Chairman: The Frontal Lobes and Neuropsychiatric Illness, American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993
42. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993
43. Course Co-director: Clinical Neuroimaging for Psychiatrists, American Psychiatric Association Annual Meeting, San Francisco, CA, May 1993
44. Meeting Chairman: Brain Imaging in Neuropsychiatry, Michael Webb Symposium Brown University, Providence, RI, October 1993
45. Lesion localization and clinical correlation in behavioral neurology, Michael Webb Symposium Brown University, Providence, RI, October 1993
46. Co-chair: Session on Neuropsychiatric Aspects of Neurologic Disease, American Academy of Neurology Annual Meeting, Washington, DC, May 1994
47. Clinical significance of subcortical encephalomalacia in early and late onset depression (Platform), American Academy of Neurology Annual Meeting, Washington, DC, May 1994
48. Symposium Chairman: Brain Imaging in Neuropsychiatry, American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994
49. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994
50. Course Co-director: Neuroimaging for Psychiatrists, American Psychiatric Association Annual Meeting, Philadelphia, PA, May 1994
51. Meeting Chairman, Symposium Chair - Subcortical Disease in Neuropsychiatry, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994
52. Utilization behavior and disinhibition in an 82 year old woman, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994
53. REM Sleep Behavior Disorder associated with a cingulate lesion, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994
54. Laryngeal botulinum toxin injection for refractory vocal tics, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994
55. Reduplicative paramnesia following lacunar infarction of the right genu of the internal capsule, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994
56. Clinical significance of subcortical encephalomalacia in early and late onset depression, American Neuropsychiatric Association Annual Meeting, Newport, RI, July 1994
57. Subcortical Vascular Disease in Aging, Rhode Island Hospital, Department of Medicine, Grand Rounds, March 1995
58. Resolution of long-standing obsessive compulsive disorder following left anteromedial thalamic infarction (poster), American Academy of Neurology Annual Meeting, Seattle, WA, May 1995
59. Neuroimaging Tutorial: An introductory software program to teach neuroimaging (poster), American Academy of Neurology Annual Meeting, Seattle, WA, May 1995

Curriculum Vitae:

Stephen P. Salloway, MD, MS

60. Course Director-Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, Miami, FL, May 1995
61. Course Co-Director-Introduction to Brain Imaging, American Psychiatric Association Annual Meeting, Miami, FL, May 1995
62. Movement Disorders in the Elderly (platform), American Psychiatric Association Annual Meeting, Miami, FL, May 1995
63. Epilepsy (platform), American Psychiatric Association Annual Meeting, Miami, FL, May 1995
64. MRI in Clinical Practice (platform), American Psychiatric Association Annual Meeting, Miami, FL, May 1995
65. CME Intensive Review of Neurology, Washington, D.C., September 1995
66. Frontal and Temporal Lobe Disorders, National CME Conference on Behavioral Disorders in the Elderly, San Francisco, CA, September 1995
67. Subcortical Vascular Disease in Aging, National CME Conference on Behavioral Disorders in the Elderly, San Francisco, CA, September 1995
68. Epilepsy and Movement Disorders, Yale-Ochsner Review Course, New Orleans, LA, September 1995
69. Scientific Program Chairman, American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995
70. Aphasia and delusions as primary symptoms in a case of multiple sclerosis (platform), American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995
71. Sexual delusions: A case series, American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995
72. Clinical profile of patients referred for evaluation of adult attention deficit hyperactivity disorder, American Neuropsychiatric Association 7th Annual Meeting, Pittsburgh, PA, October 1995
73. Advances in Clinical Neuropharmacology, Albert Einstein College of Medicine, New York, NY, October 1995
74. Frontal-Subcortical Disorders, Toronto General Hospital Department of Psychiatry Grand Rounds. November 1995
75. The New Anticonvulsants, Butler Hospital Medical Staff Association Featured Speaker, December 1995
76. Disorders of Attention, Butler Hospital Professional Lecture Series, February 1996
77. Traumatic Brain Injury, Butler Hospital Professional Lecture Series, March 1996
78. Symposium Co-Chairman: Neurology of Mood Disorders, American Academy of Neurology, March 1996
79. Biopsy proven CADASIL; pathological and radiological findings (platform), American Academy of Neurology, March 1996
80. Frontal subcortical contributions to memory (poster) (Presentation chosen for the Highlights in Behavioral Neurology Session), American Academy of Neurology March 1996

Curriculum Vitae:

Stephen P. Salloway, MD, MS

81. Advances in Vascular Dementia, Rhode Island Alzheimer's Association Caregiver Conference, May 1996
82. Brain Changes in Late-Life Depression, Department of Psychiatry Grand Rounds, Rhode Island Hospital, May 1996
83. Course Director: Clinical Neurology for Psychiatrists, American Psychiatric Association Annual Meeting, New York, NY, May 1996
84. Course Co-Director: Introduction to Brain Imaging, American Psychiatric Association Annual Meeting, New York, NY, May 1996
85. Symposium Chairman: Neuropsychiatry of Limbic and Subcortical Disorders, American Psychiatric Association Annual Meeting, New York, NY, May 1996
86. Paroxysmal Temporal Lobe Disorders Seen in Clinical Practice (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996
87. Movement Disorders in the Elderly (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996
88. Epilepsy: The New Anticonvulsant (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996
89. MRI in Clinical Practice (platform), American Psychiatric Association Annual Meeting, New York, NY, May 1996
90. Discussant: Neurology of Catatonia, American Psychiatric Association Annual Meeting, New York, NY, May 1996
91. Pathways to Recovery from Brain Injury, Butler Hospital Public Lecture Series, July 1996
92. The Aging Brain, Advances in Geriatric Medicine, Hilton Head, SC, August 1996
93. Movement Disorders in the Elderly, Advances in Geriatric Medicine, Hilton Head, SC, August 1996
94. Comprehensive Review of Neurology, Washington, DC, August 1996
95. Epilepsy and Primary Care: The New Anticonvulsants, Brown University Department of Family Medicine Grand Rounds, Memorial Hospital, Pawtucket, RI, August 1996
96. Neurological Aspects of Aging, Yale/Ochsner Neurology Review Course, New Orleans, LA, October 1996
97. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein College of Medicine, NY, October 1996
98. The Aging Brain, University of Connecticut Department of Psychiatry Grand Rounds, Farmington, CT, November 1996
99. Paroxysmal Disorders of the Limbic System, Wilford Hall Medical Center Department of Psychiatry Grand Rounds, San Antonio, TX, November 1996
100. The Aging Brain: Normal and Pathological Aging, University of Texas, San Antonio Department of Psychiatry Grand Rounds, San Antonio, TX, November 1996
101. The CADASIL Syndrome: A Genetic Form of Subcortical Dementia, American Neuropsychiatric Association 8th Annual Meeting, Orlando, FL, February 1997

Curriculum Vitae:

Stephen P. Salloway, MD, MS

102. The Executive Director's Address, American Neuropsychiatric Association 8th Annual Meeting, Orlando, FL, February 1997
103. The Aging Brain: What lesions tell us about the functional organization of the human brain, National CME Presentation, New Orleans, LA, April 1997
104. Panel member on Emerging Treatments of Dementia, Rhode Island Alzheimer's Association Annual Caregiver's Conference, April 1997
105. Comprehensive Review of Neurology CME Inc., Washington, D.C., August 1997
106. Intensive Review of Neurology, Yale/Ochsner Board Review Course, New Orleans, LA, September 1997
107. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein College of Medicine, New York, NY, October 1997
108. The Aging Brain, Opening Lecture - 10th U.S. Psychiatric Congress, Orlando, FL, November 1997
109. Welcoming Address, American Neuropsychiatric Association, Annual Meeting, Honolulu, HI, February 1998
110. The role of microvascular disease in Alzheimer's disease & vascular dementia, American Assoc. of Geriatric Psychiatry, Annual Meeting, San Diego, CA, March 1998
111. Clinical Neuroscience Update: Neuroimaging, American Assoc. of Geriatric Psychiatry, Annual Meeting, San Diego, CA, March 1998
112. Use of Imaging in Clinical Practice, American Assoc. of Geriatric Psychiatry, Annual Meeting, San Diego, CA, March 1998
113. CADASIL and Binswanger's: Neurobehavioral disorders caused by subcortical microvascular disease, Longwood Neuroscience Grand Rounds, Brigham and Women's Hospital, Boston, MA, March 1998
114. Pharmacological Management of Cognitive and Behavioral Problems Following Stroke in the Course Pharmacology of Cognition, American Academy of Neurology 50th Annual Meeting, Minneapolis, MN, April 1998
115. Clinical Research Panel Participant, Rhode Island Alzheimer's Association, Annual Caregiver Conference, Cranston, RI, April 1998
116. Advances in the Diagnosis and Treatment of Dementia, St. Luke's Hospital Department of Psychiatry Grand Rounds, New Bedford, MA, May 1998
117. Advances in the Treatment of Dementia, Rhode Island Hospital Department of Medicine Grand Rounds, Providence, RI, May 1998
118. Advances in Understanding and Treating Vascular Dementia, Alzheimer's Association Annual Meeting, Indianapolis, IN, July 1998
119. Comprehensive Review of Neurology, CME Inc., Irvine, CA, September 1998
120. Clinical Neurochemistry, Clinical Neurology for Psychiatrists, Albert Einstein College of Medicine, New York, NY, October 1998
121. SPECT Scanning in Neurology and Psychiatry, St. Elizabeth's Hospital Department of Psychiatry Grand Rounds, Boston, MA, October 1998

Curriculum Vitae:

Stephen P. Salloway, MD, MS

122. The Aging Brain, US Psychiatric Congress, San Francisco, CA, November 1998
123. Movement Disorders Recognition and Management, US Psychiatric Congress, San Francisco, CA, November 1998
124. Diagnosis and Treatment of Depression in the Elderly, Brown University Department of Family Medicine Grand Rounds, Memorial Hospital, Pawtucket, RI, November 1998
125. Advances in the Treatment of Dementia, Landmark Hospital Department of Family Medicine Grand Rounds, N Providence, RI, December 1998
126. Advances in the Diagnosis and Treatment of Dementia, Bedford VA Hospital Department of Psychiatry Grand Rounds, Bedford, MA, March 1999
127. The CADASIL Syndrome and Binswanger's Disease, Neurology Grand Rounds, Cornell University Medical Ctr., New York, NY, June 1999
128. Brain Imaging and MRI in the Diagnosis of Late-life Mental Disorders, US Geriatric Congress, Orlando, FL, June 1999
129. Comprehensive Review of Neurology, CME INC., Washington, D.C., September 1999
130. Clinical Neurochemistry, Albert Einstein College of Medicine, New York, NY, October 1999
131. Diagnosis and Treatment of Movement Disorders, US Psychiatric Congress, Atlanta, GA, November 1999
132. The Aging Brain, US Psychiatric Congress, Atlanta, GA, November 1999
133. Advances in the Management of Vascular Dementia, US Psychiatric Congress, Atlanta, GA, November 1999
134. Symposium Chair: Implications of Microvascular Disease in Managing Alzheimer's Disease, Clinical Update 2000, San Juan, Puerto Rico, February 2000
135. The Role of Microvascular Disease in Alzheimer's Disease, Clinical Update 2000, San Juan, Puerto Rico, February 2000
136. Vascular Dementia and Late-life Depression, Clinical Update 2000, San Juan, Puerto Rico, February 2000
137. The Diagnosis and Treatment of Early and Atypical Dementia, American Association of Geriatric Psychiatry Annual Meeting, Miami, FL, March 2000
138. Review of Neuropharmacology, Rhode Island State Nurses Association Advanced Psychopharmacology, Providence, RI, March 2000
139. Dementia Update, Rhode Island Academy of Family Physicians Annual Conference, Newport, RI, April 2000
140. Neuropsychiatry of Limbic and Subcortical Disorders, Third International Neuropsychiatry Congress, Kyoto Japan, April 2000
141. Advances in the Management of Dementia and Brain Imaging in Late-life Psychiatric Disorders, US Geriatric Conference, Las Vegas, NV, June 2000
142. New and Emerging Treatments for Dementia, New England Medical Center Neurology Department Grand Rounds, Boston, MA, October 2000
143. Clinical Neurochemistry, Albert Einstein College of Medicine, New York, NY, October 2000

Curriculum Vitae:

Stephen P. Salloway, MD, MS

144. Mechanisms of Neurodegenerative Diseases, US Psychiatric Congress, San Diego, CA, November 2000
145. Diagnosis of Early and Atypical Dementia, American Association of Geriatric Psychiatry 14th Annual Meeting, San Francisco, CA, February 2001
146. Differential Diagnosis of Delirium, Dementia and Depression, American Association of Geriatric Psychiatry 14th Annual Meeting, San Francisco, CA, February 2001
147. Brain Imaging in Late-Life Mental Disorders, US Geriatric Congress, New Orleans, LA, July 2001
148. New and Emerging Treatments for Dementia, US Geriatric Congress, New Orleans, LA, July 2001
149. Intensive Review of Neurology, Washington, D.C., September 2001
150. Mad Cow Disease and Other Atypical Causes of Dementia, Conference on Improving Quality of Life in the Elderly, Las Vegas, NV, October 2001
151. New Treatments for Dementia: Improving Quality of Life for Caregivers, Conference on Improving Quality of Life in the Elderly, Las Vegas, NV, October 2001
152. New and Emerging Treatments for Dementia, Brown Department of Family Medicine Grand Rounds, November 2001
153. The Aging Brain: Diagnosis and Treatment of Memory Disorders in the New Millennium, US Psychiatric Congress, Boston, MA, November 2001
154. Movement Disorders: Improved Recognition and Treatment, US Psychiatric Congress, Boston, MA, November 2001
155. Management of Behavioral Symptoms in Dementia, US Psychiatric Congress, Boston, MA, November 2001
156. Effect of APOE4 genotype on capillary basement membrane area in Alzheimer's disease, 2nd International Congress on Vascular Dementia, Salzburg, Austria, January 2002
157. MRI Subcortical hyperintensities in outpatients with geriatric depression: Results from two placebo-controlled trials, 2nd International Congress on Vascular Dementia, Salzburg, Austria, January 2002
158. MRI subcortical hyperintensities in outpatient geriatric major depression, AAGP 15th Annual Meeting, Orlando, FL, February 2002
159. Basal ganglia-subcortical dementia syndromes, AAGP 15th Annual Meeting, Orlando, FL, February 2002
160. New treatments for Alzheimer's disease, Maine Medical Center Neurology Grand Rounds, Portland, ME, March 2002
161. New approaches for research in vascular dementia, International Stroke Society, Geneva, Switzerland, May 2002
162. New treatments for Alzheimer's disease and vascular dementia, International Dementia Update for Primary Care Physicians, New York, NY, June 2002
163. Small Artery Disease in the Aging Brain, Case Western Reserve University, Cleveland, OH, July 2002

Curriculum Vitae:

Stephen P. Salloway, MD, MS

164. Vascular Dementia Overview, International Vascular Dementia Summit Consensus Conference, New York, NY, September 2002
165. Vascular dementia, Maui Clinical Update: 2002, Maui, Hawaii, September 2002
166. New treatments for vascular dementia and stroke, Battling the Big Three: Heart Disease, Cancer and Stroke, Maui, Hawaii, September 2002
167. Clinical neurochemistry, Albert Einstein College of Medicine, New York, NY, October 2002
168. The Aging Brain: New and Emerging Treatments for Memory Disorders, US Psychiatric Congress, Las Vegas, October 2002
169. Movement Disorders: Better Identification and Treatment, US Psychiatric Congress, Las Vegas, October 2002
170. Aricept Global Investigators Meeting, Meeting Co-Chair and presentations on VaD study 307: A placebo-controlled trial of donepezil in VaD and Donepezil Mild Cognitive Impairment Study, Key Biscayne, Florida, February 2003.
171. Small Artery Disease in the Aging Brain, University of Iowa Department of Psychiatry Visiting Professor, Iowa City, Iowa, April 2003
172. Differentiating Vascular Dementia from Alzheimer's Disease, Multinational Vascular Dementia Advisory Meeting, Nice, France April 2003
173. Subcortical Vascular Dementia: Binswanger's Disease and CADASIL, in Vascular Dementia and Vascular Cognitive Impairment, American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii April 2003
174. Benefits of Donepezil Treatment in Patients with Mild Cognitive Impairment. American Academy of Neurology 55th Annual Meeting, Honolulu, Hawaii, April 2003.
175. The Variable Presentation of Normal Pressure Hydrocephalus, St. Luke's Hospital Medical Grand Rounds, New Bedford, MA, May, 2003.
176. Cholinesterase Inhibitors in Vascular Dementia: A New Treatment Model? In the Symposium Challenges in Dementia, American Psychiatric Association 156th Annual Meeting, San Francisco, May, 2003.
177. Advances in the Diagnosis and Treatment of Vascular Dementia. National Stroke Association Webcast, May, 2003.
178. Co-Chair Session on Vascular Depression. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003.
179. Advances in the Diagnosis and Treatment of Vascular Dementia. 2nd Annual Dementia Congress, Washington, D.C., September, 2003.
180. Small Artery Disease in the Aging Brain. Columbia University Department of Psychiatry Grand Rounds. New York, NY, October 2003.
181. Assessing the Impact of Dementia: Evidence-Based Strategies and Therapeutic Options Pri-Med East, Boston. November, 2003.
182. New and Emerging Treatments for Memory Disorders. US Psychiatric Congress, Orlando, FL, November, 2003
183. Updates in Vascular Dementia and Stroke. US Psychiatric Congress, Orlando, FL, November, 2003.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

184. Advances in Small Artery Disease and Vascular Dementia. Dartmouth Medical School Department of Neurology Grand Rounds, Hanover NH, November, 2003.
185. CADASIL: A New Genetic Form of Vascular Dementia. International Neuropsychological Society 32nd Annual Meeting, Baltimore, MD, February, 2004.
186. New and Emerging Treatments for Memory loss. RI Psychiatric Society. February, 2004.
187. Dealing with Dementia. University of Wisconsin Psychiatric Update. March, 2004.
188. Treatment of Memory Loss from MCI through more Advanced Dementia. Beaumont Hospital Neurology Rounds. Birmingham, MI, March, 2004.
189. Treatment of Vascular Dementia. American Academy of Neurology 56th Annual Meeting, San Francisco, April, 2004.
190. Exploring Differences between Vascular Dementia and Alzheimer's Disease. American Psychiatric Association 157th Annual Meeting, New York City, May, 2004.
191. Small Artery Dementia. Boston University Alzheimer's Center Grand Rounds, Boston, May, 2004.
192. Treatment of Dementia. Brown Department of Family Medicine Grand Rounds, Memorial Hospital, Pawtucket, RI, May, 2004.
193. Imaging and Cognitive Findings in CADASIL. United Leukodystrophy Foundation Annual Meeting, DeKalb, Illinois, July 14, 2004.
194. New Opportunities for Optimal Treatment, from AD to VaD in 9th International Conference on Alzheimer's Disease satellite symposium, The Pivotal Role of Cholinesterase Inhibitors. Philadelphia, PA, July 19, 2004.
195. Advances in Early Intervention in The Memory Fitness Institute Symposium, "Treating the Spectrum of Brain Impairment", New York, NY, July 25, 2004.
196. Director of the Neurology Track and lecturer on Updates in Amnesic Mild Cognitive Impairment and Vascular Cognitive Impairment in the 3rd Annual Dementia Congress, Los Angeles, September, 2004.
197. Treatment of Amnesic MCI: Lessons Learned from the 24 Week Donepezil MCI Trial, Alzheimer's Association research roundtable Mild Cognitive Impairment Meeting, Washington, DC September, 2004.
198. Clinical Perspective on Mild Cognitive Impairment, Multi-Modal Imaging Trial Meeting, New York City, September, 2004.
199. Differential Diagnosis of Dementia in Updates in Alzheimer's Disease, Maine Medical Center, Portland, ME, October 9, 2004.
200. Dementia Update, Rhode Island American College of Physicians Internal Medicine Update, Newport, Rhode Island, October, 2004.
201. Dealing With Dementia: Now and In The Future, American Society of Clinical Psychopharmacology New York City CME Program, New York, NY, November, 2004.
202. Non-Alzheimer's Dementia, Neurology Update 2004, New York City, December. 2004.
203. Cholinesterase Inhibitors, Short-Term Symptomatic Studies. International Psychogeriatric Special Expert Conference, MCI in the Elderly and Populations at Risk, Bethesda, MD, January, 2005.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

204. How Rare is Pure VaD?, Educational Forum for the Diagnosis and Treatment of Alzheimer's Disease with Cerebrovascular Disease. Berlin, Germany, February, 2005
205. Assessing Cognitive Decline in Relation to Alzheimer's Disease. Lahey Clinic Internal Medicine Grand Rounds, Burlington, MA, March, 2005.
206. Diagnostic Criteria for Mild Cognitive Impairment and Efficacy of Donepezil as Treatment for Mild Cognitive Impairment, Thailand Neurological Society Annual Meeting, Bangkok, Thailand, March 2005.
207. Key Lessons Learned from the Donepezil 24 week Mild Cognitive Impairment Trial, 3rd Annual Wein Center, University of Miami MCI Symposium, Miami, Florida, March, 2005.
208. Vascular Dementia: Clinical Aspects, Treatment and Prevention, American Academy of Neurology 57th Annual Meeting. Miami, FL, April, 2005.
209. Early Diagnosis and Treatment of Alzheimer's disease. 46th Annual Meeting of the Societas Neurologica Japonica, Kagoshima, Japan, May, 2005.
210. Treatment of Mild Cognitive Impairment. Eisai Tsukuba Laboratory, Tsuchiura, Japan, May, 2005.
211. Vascular Dementia and Alzheimer's Disease: Clinical-Pathological Correlations. 2nd Congress of the International Society for Vascular Behavioral and Cognitive Disorders. Florence, Italy, June, 2005.
212. Symposium Chairman: Cholinergic Treatment Across the Spectrum of Dementia and Lecturer: Management of MCI and Early Dementia. International Psychogeriatric Association 12th Congress, Stockholm, Sweden, September, 2005.
213. Neurology Track Chair, 4th Annual Dementia Congress and Lecturer: Early Diagnosis and Treatment of Alzheimer's Disease. Atlanta, GA, October, 2005.
214. Management of Early Dementia. Jewish General Hospital Geriatric Medicine Grand Rounds, Montreal, CA, November, 2005.
215. Early Diagnosis and Treatment of Alzheimer's Disease. Alzheimer's Services of Cape Cod 8th Annual Alzheimer's Awareness Conference, Mashpee, MA, November 2005.
216. Management of MCI and Early Alzheimer's Disease. 57th Annual Meeting of the Spanish Neurological Society, Barcelona, Spain, November, 2005.
217. CADASIL: A Genetic Cause of Stroke and Vascular Cognitive Impairment. Neurology Grand Rounds, Cooper University Hospital, Camden, New Jersey, January, 2006.
218. Vascular Dementia and Vascular Cognitive Impairment: Treatment Approaches. Rotman Research Institute 16th Annual Conference Stroke and Cognition. Toronto, Canada, March, 2006.
219. Current Concepts in Mild Cognitive Impairment. American Association of Geriatric Psychiatry 19th Annual Meeting, San Juan Puerto Rico, March, 2006.
220. Treatment of Early Dementia. Department of Neurological Sciences. Centre Hospitalier, University Laval. Quebec, Canada, May, 2006.
221. CADASIL: A Genetic Model of Stroke and Small Artery Dementia. Vancouver General Hospital/University of British Columbia Neuroscience Rounds. Vancouver, CA, May, 2006.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

222. Diagnosis and Management of Early Alzheimer's Disease. Glenrose Rehabilitation Hospital Geriatric Grand Rounds, Edmonton, Alberta, CA, May, 2006.
223. Diagnosis and Treatment of Mild Cognitive Impairment: Now and In the Future. The 22nd Annual Alzheimer's Disease Symposium. Alzheimer's Association East Tennessee Chapter, Gatlinburg, Tennessee, June, 2006.
224. Diagnosis and Management of MCI and Early AD: Now and in the Future. Worcester Medical Center Neurology Grand Rounds. Worcester, MA, June, 2006.
225. CADASIL: Pathobiology and Clinical Phenotype. West Virginia University School of Medicine Department of Neurology Grand Rounds. Morgantown, West Virginia, July, 2006.
226. CADASIL: A Genetic Cause of Stroke and Vascular Dementia. Beth Israel Phillips Medical Center Neurology Grand Rounds. New York, NY, September, 2006.
227. Understanding the Clinical and Genetic Phenotype of CADASIL. Long Island Jewish Medical Center Department of Neurology Grand Rounds, Great Neck, NY, October, 2006.
228. Genetics of Dementia. Cooper University Hospital Neurology Grand Rounds, Camden, New Jersey, November, 2006.
229. Neurology Track Chair, Fifth Annual Dementia Congress, Orlando, FL, November, 2006
a) Diagnosing and Treating MCI: Now and in the Future, b) Practical Tips for Diagnosing and Treating Vascular Cognitive Impairment, c) Case Study Challenge
230. CADASIL and Inherited Dementias. Neurogenetics for the Practitioner. New York University, New York, November, 2006.
231. 2006 US Psychiatric Congress. New Orleans, LA, November, 2006.
a) Alzheimer's Disease Centennial Lecture, b) Differential Diagnosis of Dementia, c) Diagnosis and Treatment of Movement Disorders.
232. CADASIL and Inherited Dementia. Army Medical Department Neurology 26th Annual Meeting. San Antonio, TX, November, 2006.
233. CADASIL: Stroke, Genetics, and Dementia. University of Utah Neurology Grand Rounds, Salt Lake City, Utah, January, 2007.
234. Current Controversies in Vascular Cognitive Impairment session co-chair, American Heart Association International Stroke Conference, San Francisco, CA, February, 2007.
235. Taking The Next Steps in Alzheimer's Disease. Symposium Chair and lecturer, Disease-Modifying Agents for AD. American Association of Geriatric Psychiatry 2007 Annual Meeting. New Orleans, LA, March, 2007.
236. 5th Annual Mild Cognitive Impairment Symposium: Toward an Earlier Diagnosis of Alzheimer's Disease. Discussant-"Next Steps". Mount Sinai Medical Center. Miami, Florida, April, 2007.
237. CADASIL: Arteriolar Degeneration, White Matter Injury and Dementia. Neurology Grand Rounds Tufts New England Medical Center, Boston, MA, June, 2007.
238. Clinical-Pathological Case Presentations: Exploring the interface between degenerative and vascular dementia and Chair: Defining Small Vessel Disease Dementia. 3rd International Vas-Cog Congress. San Antonio, July 2007.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

239. CADASIL: Arteriolar Degeneration, Stroke, and Dementia. Albany Medical Center Neurology Grand Rounds, Albany, NY, October, 2007.
240. Diagnosing Alzheimer's Disease Before Dementia. Plenary lecture at the 4th Canadian Colloquium on Dementia. Vancouver, Canada, October, 2007.
241. Neurology Track Chair and Lecturer 1) Diagnosing Alzheimer's Before Dementia 2) The Interface Between Vascular and Degenerative Dementia 3) Clinical Pathological Correlations 6th US Dementia Congress Chicago, IL November, 2007
242. CADASIL: Arteriolar Degeneration, Stroke and Dementia. Hartford Hospital Neurology Grand Rounds Hartford, CT, January, 2008.
243. CADASIL and Vascular Contributions to Dementia. St. Vincent's Hospital Neurology Grand Rounds Worcester, MA, January, 2008.
244. MCI: Results of Studies with Cholinesterase Inhibitors in Clinical Relevance and Treatment Update in MCI 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy. Hong Kong, China February, 2008.
245. Evidence-based Strategies for Managing Alzheimer's Disease. Washington Academy of Family Physicians 59th Annual Scientific Assembly. Cle Elum, WA, May, 2008.
246. Early Diagnosis and Treatment of Alzheimer's Disease. Yale University Department of Neurology Grand Rounds. New Haven, CT, June, 2008.
247. CADASIL and Vascular Contributions to Dementia. Bridgeport Hospital Department of Medicine Grand Rounds. Bridgeport, CT, June, 2008.
248. Early Recognition and Treatment of Alzheimer's Disease, Symposium Chair and lecturer- Optimizing Treatment Outcomes in the Era of Disease Modification. International Congress of Alzheimer's Disease 2008, Chicago, IL, July, 2008.

MEDIA REPORTS:

Beneficial Effects of Glycine on Memory, WebMD, 1/5/00

Alcohol Consumption as a Risk Factor for Alzheimer's Disease, Channel 7 News, 6/14/00

New Treatments for Alzheimer's Disease, Providence Journal, 8/2/00

Highlights of the World Alzheimer Congress, Providence Business News, 8/6/00

Caregiver Burden, CBS Healthwatch, 10/6/00

Depression as a Prodrome of Dementia, Channel 10 Health Check 3/02

Estrogen for Prevention of Alzheimer's Disease Channel 10 Health Check 6/02

MRI Subcortical Hyperintensities and Response to Sertraline and Citalopram in Geriatric Depressed Outpatients, AAGP, 2002 Meeting Symposia Highlights, 19-20

Vascular Dementia Satellite TV Media Broadcast, Chicago, IL, Medical update on vascular dementia broadcast to over 20 regional TV news programs, October 1, 2002

New Treatments for Memory Loss Due to Stroke, Channel 10 Health Check, Dec. 11, 2002

New Treatments for Vascular Dementia, Channel 12 News Health Report, Jan. 7, 2003

New Treatments for Memory Loss, NESN TV Health Report, February, 2003

Curriculum Vitae:

Stephen P. Salloway, MD, MS

First Cholinesterase Inhibitor for Mild Cognitive Impairment, Medscape.com, April, 2003
Advances in Vascular Dementia, Public Broadcasting American Medical Review, May, 2003
Cholesterol and Alzheimer's Disease, Channel 10 Health Check, June, 2003
New Treatments for Mild Cognitive Impairment, Channel 10 Health Check, June, 2003
New Treatments for Memory Loss, ABC World News Tonight, August 21, 2003
New Treatments for Memory Loss, A Touch of Gray, September 8, 2003
Research Advances and President Reagan's Alzheimer's Disease, Newsweek June 20, 2004
Treatment of Mild Cognitive Impairment, ABC World News Tonight, July 18, 2004
New Trials for Mild Cognitive Impairment, Channel 10 Health Check, September 13, 2004
New Targets for the Treatment of Alzheimer's Disease, Channel 10 Health Check, November 12, 2004
Cardiac Complications in Trials of Non-Steroidal Anti-Inflammatory Agents for Alzheimer's Disease, Channel 10 Health Check, December, 2004.
Assessment of the Persistent Vegetative State: The Case of Terri Schiavo, Boston Globe 3/23/05.
Vascular Dementia: Clinical Aspects, Treatment and Prevention. MD Net Guide.Com, April 9, 2005.
Three Year Comparison of Donepezil, Vitamin E, and Placebo for Mild Cognitive Impairment. ABC World News Tonight and Bloomberg Wire Services, April 13, 2005
Donepezil, Vitamin E, and Placebo for Mild Cognitive Impairment. Good Morning America, 4/14/05.
Treatment of AD with an Amyloid Vaccine, Channel 10 Health Check, July, 2005.
CADASIL: A Genetic Form of Stroke Causing Migraine and Memory Loss Channel 10 Health Check, September 12, 2005.
New Leuprolide Implant Trial to Slow Progression of Alzheimer's Disease, Channel 10 Health Check, and NBC and MSNBC national news, December 15, 2005.
Development of an Active Amyloid Vaccine to slow progression of Alzheimer's Disease, Channel 10 Health Check, April 3, 2006.
CADASIL: A New Disease Causing Migraine, Memory Loss, and Stroke. Fox9 News Minneapolis, MN, January 22, 2008.
Good News for the Forgetful: Aging Needn't Wipe Memory. Chicago Tribune February 19, 2008.
Update on Vaccine Treatment for Alzheimer's Disease. NBC Channel 10 Health Check. May 30, 2008.
Familial Alzheimer's Disease. NBC Channel 10 Health Check. July 3, 2008.
Results of the Flurizan and Amyloid Vaccine Trials NBC Channel 10 Health Check. July 9, 2008.
Amyloid-based Immunotherapy for Alzheimer's Disease. NBC Nightly News, July 29, 2008.

RESEARCH INTERESTS

1. Pathophysiology and genetic features of subcortical microvascular disease in aging, including vascular changes in Alzheimer's disease and the CADASIL syndrome.
2. Clinical trials for Alzheimer's disease, mild cognitive impairment, and vascular dementia,.
3. Executive function and disability.

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Resources: Quantitative neuroimaging laboratory, transgenic animal facility, comprehensive neuropsychological assessment, ambulatory blood pressure monitoring, MRI/autopsy protocol, multidisciplinary clinical research team, collaboration with investigators from other departments in the Medical School.

GRANTS

1. Sleep patterns in people over age 75
National Institute on Aging
\$15,000.
1982 – 1983
Role: Principal investigator.
2. A trial of gamma knife anterior capsulotomy to treat refractory obsessive compulsive disorder. A collaborative trial by Brown University, Massachusetts General Hospital and the Karolinska Institute. Jenike M, Rasmussen S. Principal Investigators
1992-present
Role: Investigator assisting with neurological assessment and quantitative imaging analysis.
3. Imitrex post-marketing surveillance study: a multi-center study
Glaxo Pharmaceuticals S2B-350
1994-5
Role: Investigator
4. A multi-center, randomized double-blind, comparative study of gabapentin administered as an initial dosage of 900 mg/day versus a dosage titrated to 900 mg/day over three days.
Parke-Davis Pharmaceuticals 945-090
\$3,610.
1994-5
Role: Investigator
5. Subcortical vascular disease in aging
Neurology Foundation Faculty Development Fund
\$18,000.
1994-5
Role: Principal Investigator
6. Quantitative MRI analysis of subcortical white matter changes in late-life onset depression
Brown University Department of Psychiatry and Human Behavior Pilot Project Grant.
1992-3-\$30,000.
1994-5-\$16,000.
Role: Principal Investigator
7. Longitudinal course of subcortical cerebrovascular disease in late-life depression: an MRI follow-up study. Jenkins M-PI
Butler Hospital Faculty Research Fund
\$25,000.
1995-6
Role: Co-investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

8. Subcortical vascular disease in geriatric hypertension
Surdna Foundation Fellowship for Research in Gerontology
\$15,000.
1995-6
Role: Principal Investigator
9. Cognex: neuropsychiatric testing and assessment of caregiver time
Parke-Davis Pharmaceuticals 970-87
\$2,000
1996-7
Role: Investigator
10. Vascular predictors of depression and cognitive impairment in the elderly.
Brown University, Dept. of Psychiatry and Human Behavior Pilot Project Grant
\$20,000
1996-7
Principal Investigator
11. Effect of pemoline on measures of attentional performance in adult ADHD
Abbott Laboratories
\$4,000
1996-7
Principal Investigator
12. An open-label trial of donepezil for the treatment of Alzheimer's disease
Pfizer/Esai Pharmaceuticals E2020-A001-313
\$22,500
1996-7
Co-Principal Investigator
13. Neuropathological, neuroimaging and neuropsychological features of CADASIL.
American Heart Association Grant-in-Aid 9706211S
\$20,000
1997-9
Principal Investigator
14. An eight-week, parallel group, double-blind, placebo-controlled study of sertraline in elderly outpatients with DSM-IV major depression. Martin Keller-PI
Pfizer Pharmaceuticals R-0552
\$71,000
1997-8
Brown site administrator, Co-investigator
15. Relationship of MRI hyperintensities to treatment response in geriatric depression.
Pfizer Pharmaceuticals R-0552 MRI study
\$150,000
1997-2000
Principal Investigator with Ranga Krishnan, M.D. of Duke for this multi-center study

Curriculum Vitae:

Stephen P. Salloway, MD, MS

16. Metrifonate Nationwide Investigational Trial
Bayer Pharmaceuticals D-97-019
\$10,000
1997-8
Principal Investigator
17. A 24 week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease. Eisai Inc. E2020-A001-307
\$ 130,000
1998-2001
Principal Investigator, Brown site
18. A multi-center, double-blind comparison of efficacy and safety of Seroquel, haloperidol, and placebo in the treatment of elderly subjects residing in nursing homes or assisted care facilities and Presenting with Alzheimer's dementia and psychoses or other selected psychoses.
Zeneca Pharmaceuticals 5077IL/0039
\$120,000
1998-9
Investigator and administrator of the Brown site
19. A randomized, double-blind, placebo-controlled trial of citalopram in depressed patients at least 75 years of age.
Forest Laboratories CIT-MD3-97-03-000
\$130,000
1998-
Investigator, Brown site administrator
20. Subcortical microvascular disease in geriatric depression
National Institute of Mental Health 1 K08 MH01487
\$752,994
1999-2004
Principal Investigator
21. A 24-week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment.
Eisai E2020-A001-401
\$110,000
1999-2000
Co-Principal Investigator with Paul Malloy, Ph.D.
22. A multi-center, randomized, double-blind, placebo-controlled trial of estrogen to prevent Alzheimer's disease in women at risk.
National Institute on Aging RO 1AG15922/Columbia University
\$146,000
1999-2003
Principal investigator, Brown site

Curriculum Vitae:

Stephen P. Salloway, MD, MS

23. Combined behavioral and pharmacological intervention to improve memory in Alzheimer's disease
Alzheimer's Association Investigator Award (Deborah Cahn-Weiner PI)
\$80,000
1999-2001
Consultant
24. Improving sleep and cognitive functioning in Alzheimer's disease
Eisai/Pfizer Investigator Award (Mark Aloia PI)
\$100,000
1999-2001
Investigator
25. Genetic Models of Human Dementia
P20 RR15578-01 (a project of the Brown Center for Genetics and Genomics COBRE total grant \$11,219,863)
\$1,013,374
2000-2005
Co-Principal Investigator (Justin Fallon, subproject PI)
26. Heart Disease, CNS Dysfunction and Outcome in the Elderly
NIH 1050258905
\$1,753,134 (Ronald Cohen, PI)
2000-2005
Investigator
27. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment clinically at risk for development of clinically probable Alzheimer's disease.
Janssen GAL-INT-11
\$300,000
2001-4
Principal Investigator
28. A randomized, 30-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease
Janssen Research Foundation GAL-INT-26
\$125,000
2001-3
Principal Investigator
29. Functional impairment in Alzheimer's disease and normal aging
National Institute on Aging
AG05898-01 (Patricia Boyle, PI)
\$60,000
2000-2
Consultant/Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

30. Treatment of apathy in Alzheimer's disease
Alzheimer's Association, (Patricia Boyle, PI)
\$100,000
2001-3
Consultant/Investigator
31. Electrical stimulation of the internal capsule for intractable OCD and depression (Ben Greenberg, P.I.)
Medtronics
2001-present
Investigator assisting with neurological assessment and quantitative imaging analysis
32. A double-blind, randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and GI tolerance in patients with mild-moderate Alzheimer's disease
Janssen Pharmaceutica
\$100,000
2002-
Principal Investigator
33. A telephone intervention for dementia caregivers
NIMH R21 MH62561, (Geoffrey Tremont, PI)
\$576,042
2002-5
Consultant/Investigator
34. An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease (Protocol # A2581078)
Pfizer, Inc.
2003-5
\$274,240
Principal Investigator
35. NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI)
\$1,492,665
2003-2008
Description: Dementia research fellowship for 2, 2-year post-docs in 2003 increasing to 4 2-year positions.
co-PI with Richard Besdine
36. A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy, safety and tolerability of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-319)
Eisai Medical Research, Inc.
2003-
\$81,336
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

37. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of Titration and Treatment with C105 in Subjects with Mild Cognitive Impairment (MCI) (Protocol # 22020)
Sention Inc.
2003
\$157,400
Co-Principal Investigator
38. Efficacy and Safety of LY451395 in Patients with Probable Alzheimer's Disease (Protocol #H6N-MC-LEAM)
Lilly Pharmaceuticals
2003
\$101,856
Principal Investigator
39. Working memory and frontal white matter integrity in mild cognitive impairment
Alzheimer's Association (Stephen Correia, Ph.D., PI)
NIRG-03-6195
2003-5
\$100,000
Mentor and investigator
40. An open-label, multi-center, one-year extension of the evaluation of donepezil hydrochloride (E2020, Aricept®) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-320)
Eisai Medical Research, Inc.
2003-2005
\$62,964
Principal Investigator
41. A 51 week, , multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment (Protocol # E2020-A001-412)
Eisai Medical Research, Inc.
2004-
\$128,832
Principal Investigator
42. Galantamine ER open label rapid dose escalation trial in Alzheimer's disease (Protocol # GAL-ALZ-303)
Janssen Pharmaceutica Products, L.P.
2004-2005
\$32,000
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

43. A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease (Protocol ONO-2506POU010)
Ono Pharmaceutical Co., Ltd.
2004-
\$214,890
Principal Investigator
44. A phase III study of the efficacy and safety of Alzhemed™ in patients in mild to moderate Alzheimer's disease (Protocol CL-758007)
Neurochem, Inc.
2004-
\$462,000
Principal Investigator
45. An open-label, 8-week clinical trial of the safety and efficacy of Escitalopram for the treatment of depression and anxiety in dementia caregivers
Forest Laboratories
2005-
\$106,111
Principal Investigator
46. Aging Brain: DTI, Subcortical Ischemia and Behavior
1 R03 AG023916-01A1
2005-2007
\$120,000
Principal Investigator
47. Metrics for Quantifying White Matter Variation: Image Analysis, Testing and Application
Brown Vice-President Seed Grant
2005-6
\$100,000
David Laidlaw, PI (Co-Investigator)
48. Treatment of apathy in Alzheimer's disease with modafinil
1 F32 MH075583-01
2005-2007
Laura Frakey, Ph.D., PI, (co-mentor with Dr. Malloy)
49. Phase 3 Multi Center, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type (MPC-7869-04-005.03)
Myriad Pharmaceuticals, Inc.
2005-
\$161,772
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

50. A Phase IIa Multicenter, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 (ELN116727) in Patients with Mild to Moderate Alzheimer's Disease (AAB-001-210)
Elan Pharmaceuticals, Inc
2005-
\$196,482
Principal Investigator
51. A Phase I, Multicenter, Randomized, Blinded, Single Ascending Dose, Safety, and Tolerability Trial of ACC-001 (QS-21) in Patients with Mild to Moderate Alzheimer's Disease (ACC-001-10)
Elan Pharmaceuticals, Inc
2005-
\$181,454
Principal Investigator
52. A Double-Blind Placebo-Controlled Study of VP4896 For The Treatment Of Mild-To-Moderate Alzheimer's Disease (VP-AD-301)
Voyager Pharmaceutical Corporation
2005-
\$276,000
Principal Investigator
53. Alzheimer's Disease Neuroimaging Initiative ADNI-024
NIA U01 AG10483
2006-
\$330,825
Principal Investigator
54. An 18 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.
Eisai
2005-6
\$160,000
Principal Investigator, Steering Committee Member, assisted with study design
55. A 54' week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APO ϵ 4-stratified subjects with mild to moderate Alzheimer's disease
Glaxo Smith Kline
2006-
\$250,000
Principal Investigator

Curriculum Vitae:

Stephen P. Salloway, MD, MS

56. Inter-rater reliability between expert and non-expert-physicians in the diagnosis of amnesic MCI in the community setting A2501051/E0000-A001-001
Pfizer, Eisai
2006-
\$23,000
Principal Investigator, Consensus Committee Member
57. A phase IIa, multicenter, randomized multiple ascending dose, safety, tolerability and immunogenicity trial of ACC-001 with QS-21 adjuvant (amyloid vaccine trial) in patients with mild to moderate Alzheimer's Disease
Wyeth ACC-001 3134K1-2201
2007-present
\$790,649
Principal Investigator
58. Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease
Eisai
2007-present
\$140,000
Principal Investigator

HOSPITAL AND UNIVERSITY TEACHING ROLES

- 1980-1981 **University of California Berkeley**
Teaching Assistant for the course: Human Growth and Development for medical and graduate students.
- 1983-1985 **Stanford Medical School**
Coordinator of the psychiatry and behavioral science curriculum in the Primary Care Program
Instructor for the course: Introduction to Clinical Medicine
- 1989-1991 **Yale University**
Director of the course: Behavioral Neurology - for medical students Seminar
Director: Neuroradiology/Clinical Correlations for the psychiatry housestaff and attending staff at Yale-New Haven Hospital
Co-director of the bi-weekly Movement Disorder seminar at Yale University
Instructor for the neurology section in The Introduction to Clinical Medicine Course for Medical Students
- 1990-1995 **Yale University**
Co-director of the course: Comprehensive Review of Neurology
Offered 2 times per year
- 1991-present **Brown University**

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Undergraduate Education

Director of an Independent Study Course in neurobehavioral research for undergraduates majoring in neuroscience and biology (B195/196) (1-3 students per semester, includes honors thesis for eligible seniors).

Lisa Israeli, Neuroscience, fall and spring semesters 1994-5 and 1995-6.

Project: Development of a brain imaging rating scale. Co-author of one peer reviewed paper and one abstract.

Kathy Chang, Neuroscience, spring 1994-95, fall 1995-96.

Project: Clinical profiles of adults presenting with attentional disturbance. Honorable mention for the ANPA Young Investigator Award for abstract #12 at the American Neuropsychiatric Association Annual Meeting 1995.

Mary Lynn Mercado, Biology, spring 1994-95, fall and spring semesters 1995-96. Senior honors thesis: Subcortical vascular disease and late-life depression

Joseph Hong, Neuroscience, spring semester 1995-96, University Teaching and Research Assistant (UTRA) summer 1996, fall, spring 1996-97 Projects: I. Effect of pemoline on cognitive performance, II. Honors thesis. MRI and small artery changes in CADASIL and Binswanger's disease. Author of two peer-reviewed papers and Presentation at two national meetings

Jorge Intal, Neuroscience, summer 1996, fall, spring 1996-97

Project: Cerebral microvascular disease in aging: I. A comparison of FLAIR and PD MRI sequences and II. MRI-autopsy correlation of signal hyperintensities. Presented at the Society for Neuroscience 27th Annual Meeting, New Orleans (abstract #21).

Maureen Cruz, Biology, fall 1997

Project: Cerebral perfusion abnormalities in normal pressure hydrocephalus.

Mary Pan, Neuroscience, fall and spring 1998-9

Project: Neuropsychiatric symptoms in vascular dementia

Susan Rymer, Anthropology, fall and spring 1999-2000

Project: Awareness of cognitive deficit in Alzheimer's disease and caregiver burden

Tamar Gur, Biology Honors Thesis second reader, 1999-2000

Project: ApoE4 and agrin staining of microvascular integrity in Alzheimer's disease (co-mentor with Dr. Stopa)

Ellen Kotwas, spring 1999-2000, summer and fall 2000-2001

UTRA Fellow, Psychology Honors Thesis

Project: Affective and semantic priming in Alzheimer's disease

Awarded the Muriel Fain Sher Premium in Psychology by the Department of Psychology for her honors research (co-mentor with Dr. Heindel)

Audrey Kwak, 2001-2, Psychology Honors Thesis

Project: Predictors of functional impairment in Alzheimer's disease

Leah Belsky, 2001-2 Biology

Project: When familial FTD is suspected: Ethical and clinical issues in genetic research

Sophie Desbiens, Summer 2002 Brain Science UTRA Fellow

Project: Development of an assay for notch-3 mutations

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Suzanne Drodge, Summer 2002 MRI Research Facility UTRA Fellow

Project: Diffusion tensor imaging in CADASIL

Stan Pelosi, Summer 2002 PLME summer research assistantship

Project: Working memory in Alzheimer's disease (co-mentor with Dr. Malloy)

Jonathan Greer, 2003 PLME summer research assistantship

Project: A PCR-SSCP reliant assay for notch-3 mutations in CADASIL patients

Irmak Turan, Barrington High School Senior Project (awarded honors)

Project: Is Down's syndrome a good genetic model for studying Alzheimer's disease?

Ryan Li, 2003-4 Neuroscience honors thesis

Project: MRI correlates of ambulation and motor functioning in Alzheimer's disease.

Thea Brennan-Krohn, 2004 Summer Training in Aging Research Topics Mental Health- NIMH

Award- Diffusion tensor imaging and working memory in SIVD. 2005 Summer Training in Aging Research Topics Mental Health NIMH Award- Molecular analysis of notch and notch ligand expression in vascular dementias

Christopher Song, 2004 Summer Training in Aging Research topics Mental Health- NIMH Award

Project: Development of an assay for notch3 mutations

Sharon Song, 2007 Biology concentrator honors thesis (co-mentor with Stephen Correia, PhD)

Project: MOCA is more sensitive than MMSE in MCI because of executive dysfunction..

Brown Medical Student Education

Director of the second semester, first year course. The Human Brain and Behavior (Biomed 370)

Co-leader of a small group and lecturer in the Neurologic Pathophysiology Course for second year students (Neurosciences 262)

Director, Neuropsychiatry and Behavioral Neurology Elective (Biomed 515)

Extended Medical Student Research Elective

Ximena Morales, 1994-95, Medical School Columbia, South America, six month neurobehavioral research elective in geriatric depression

Shirine Nassery, PLME summer research assistantship 2001

Relationship of subcortical microvascular changes in Alzheimer's disease to ApoE genotype and systolic hypertension

Risha Kopel, summer research project 2001

Use of diffusion tensor MRI to differentiate normal pressure hydrocephalus from Alzheimer's disease

Tyler Berzin, 2001-2, Brown Faculty Scholars Award recipient

Microvascular changes in Alzheimer's disease (co-mentor with Dr. Stopa)

Ari Blitz, 2000-1, Brown faculty Scholars recipient

Alterations in frontal-subcortical circuits in OCD

Ainsley MacLean, 2002 PLME summer research assistantship

Phenotypic variation in a large family with CADASIL, Recipient of an Alzheimer's Association Travel Award to present her work at the 8th World Alzheimer's Disease Congress in Stockholm, 7/2002

Colleen Craig 2005 3rd year medical student 6 month longitudinal neurology elective

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Michael Joseph, Summer 2005, Clinical Neuroscience Mental Health Research Training-R25 MH 60477-05 Relationship of hippocampal and whole brain volume to cognitive impairment in CADASIL

James Enos, 2008 Summer Training in Aging Research Topics Mental Health NIMH Award, Normal pressure hydrocephalus: clinical-pathological correlations. primary mentor with Dr. delaMonte.

Brown Post-graduate Medical Education

Director of the American Board of Psychiatry and Neurology/ACGME-Approved 855-43-44-005 Brown University Combined Residency Training Program in Neurology and Psychiatry.

NIA ZAG1 FAS-5 J1 Institutional National Research Service Award

Dementia Research Fellowship T-32 (Paul Malloy, PI) 2003-2008, co-PI with Richard Besdine

Director of the Neuropsychiatry/Behavioral Neurology Fellowship

Director of the Neuropsychiatry Track in the Psychiatry Residency

Neurology Ward and Consultation Service Attending - Rhode Island Hospital

Neurology Consultation Service Attending - Butler Hospital

Behavioral Neurology Outpatient Elective Rotation Attending

Mentor, Brown Psychiatry Residency Research Track

Lecturer in the Brown University Neuropsychology Training Seminar

Lecturer in the weekly neurology resident seminar series

Lecturer in the Geriatric Psychiatry and Geriatric Medicine fellowship programs

Lecturer on Geriatric research in the Brown University NIH T-32 Young Investigator Training Seminar

Director of the Brown University Neuropsychiatry/Behavioral/Neurology Grand Rounds Series- Butler Hospital

Co-director of Brown University Neuroradiology Rounds – Butler Hospital.

Brown Medical School Extended Resident Electives

Cleve Shirey, M.D. Senior Psychiatry Resident, 1993-4, Year-long one-half day weekly neuropsychiatry outpatient continuity clinic

Suda Bakshi, M.D. Triple Board Resident in Pediatrics, Child Psychiatry and Adult Psychiatry, 1994-5, Nine month one-half day weekly neuropsychiatry outpatient clinic

Jeffrey Daly, M.D. Senior Psychiatry Resident, 1994-5, Twelve month, part-time elective in neuropsychiatric research. Published two peer-reviewed articles and one book chapter and was selected for the American Psychiatric Association Burroughs-Wellcome Award.

Neeta Jaine, M.D. Senior Psychiatry Resident, 1995-6, Four month weekly neuropsychiatry outpatient continuity clinic

Ron Neeper, M.D., Ph.D., Triple Board Resident in Pediatrics, Child Psychiatry and Adult Psychiatry and Pediatric Neurology Resident 1994-6, Two year neuropsychiatry continuity clinic two half-days/week

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Gary Epstein-Lubow, M.D., Senior Psychiatry Resident, Four month weekly neuropsychiatry outpatient elective 2001, Project-Neuropsychiatric aspects of NPH

Combined Residents in Neurology and Psychiatry

Curt LaFrance, M.D., 1995-2001

Current position: NIMH Research Fellow at Rhode Island Hospital. Recipient of a NINDS Career Development Award 2003-8.

Rochelle Woods, M.D., 1999-present

Research project: Validating a scale for measuring outcome from intracerebral hemorrhage.

Neuropsychiatry Fellows

John Campbell, M.D., 1992-1993

Published two peer-reviewed papers and made two Presentations at national meetings during the fellowship. Current Position-Director of Neuropsychiatry, Henry Ford Hospital, Detroit, MI

Colin Harrington, M.D., 1996-97

Current position-Director of Consultation-Liaison Psychiatry, Rhode Island Hospital. Dr. Harrington received the 2003 Senior Citation Award for best faculty mentorship from the 2003 Brown Medical School graduating seniors.

T-32 Post-Doctoral Research Fellows

Stephen Correia, Ph.D., 2003-2005

Working memory and frontal white matter integrity in mild cognitive impairment (mentor)

Gary Lubow, M.D., 2003-2005

Treatment of depression in dementia caregivers (co-mentor with Van Miller, Ph.D.)

Visiting Scholars

Paul O'Hara, M.D., 1998-2000, University of Western Australia

Research supervisor, Controlled treatment trials for vascular dementia

Neuropsychology Post-Doctoral Fellows

Deborah Cahn-Weiner, Ph.D., 1996-98

Research Supervisor, Cognitive performance and functional status in normal aging and dementia (co-mentor with Dr. Malloy)

Current position-staff psychologist Memorial Hospital of RI

Lauren Norton, Ph.D., 1998-2000

Research Supervisor, Behavioral symptoms and activities of daily living in dementia (co-mentor with Dr. Malloy)

Current position staff psychologist Massachusetts General Hospital

Patricia Boyle, Ph.D., 2000-2002

Research supervisor, NIA F-32 Executive function and activities of daily living in Alzheimer's disease (co-mentor with Dr. Malloy)

Current position Director of Neuropsychology BU Alzheimer's Center

Stephen Correia, Ph.D., 2002-2005

Research supervisor, NIA T-32 Dementia Research Fellow

Diffusion tensor imaging of frontal systems in mild cognitive impairment. (co-mentor with Dr. Malloy)

Curriculum Vitae:

Stephen P. Salloway, MD, MS

Ryan Garrity, Ph.D., 2000-2002

Research supervisor, A trial of estrogens for prevention of Alzheimer's disease (co-mentor with Dr. Malloy) Current position-staff psychologist

Heather Belanger, Ph.D., 2002-2003

Research supervisor, Diffusion tensor imaging and executive function in Alzheimer's disease (co-mentor with Dr. Malloy)

Kelly Wilder-Willis, Ph.D., 2002-2004

Research supervisor, Working memory in Alzheimer's disease (co-mentor with Dr. Malloy)

Laura Frakey, Ph.D., 2005-2007

Research supervisor, Treatment of apathy in Alzheimer's disease with modafinil (co-mentor with Dr. Malloy)

LANGUAGES German, Hebrew